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stract
Th
e
C
on
cise
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y
2017/18
provides
con
cise
overview
s
of
th
e
key
properties
of
n
early
1800
h
um
an
drug
targets
w
ith
an
em
ph
asis
on
selective
ph
arm
acology
(w
h
ere
available),
plus
lin
ks
to
an
open
access
kn
ow
ledgebase
of
drug
targets
an
d
th
eir
ligan
ds
(w
w
w
.guidetoph
arm
acology.org),w
h
ich
provides
m
ore
detailed
view
s
of
target
an
d
ligan
d
properties.
A
lth
ough
th
e
C
on
cise
G
uide
represen
ts
approxim
ately
400
pages,th
e
m
aterial
presen
ted
is
substan
tially
reduced
com
pared
to
in
form
ation
an
d
lin
ks
presen
ted
on
th
e
w
ebsite.
It
provides
a
perm
an
en
t,citable,poin
t-in
-tim
e
record
th
at
w
ill
survive
database
updates.
Th
e
full
con
ten
ts
of
th
is
section
can
be
foun
d
at
h
ttp://on
lin
elibrary.w
iley.com
/doi/10.1111/bph
.13879/full.
Ligan
d-gated
ion
ch
an
n
els
are
on
e
of
th
e
eigh
t
m
ajor
ph
arm
acologicaltargets
in
to
w
h
ich
th
e
G
uide
is
divided,w
ith
th
e
oth
ers
bein
g:
G
protein
-coupled
receptors,voltage-gated
ion
ch
an
n
els,oth
er
ion
ch
an
n
els,n
uclear
h
orm
on
e
receptors,catalytic
receptors,en
zym
es
an
d
tran
sporters.Th
ese
are
presen
ted
w
ith
n
om
en
clature
guidan
ce
an
d
sum
m
ary
in
form
ation
on
th
e
best
available
ph
arm
acologicaltools,alon
gside
key
referen
ces
an
d
suggestion
s
for
furth
er
readin
g.Th
e
lan
dscape
form
at
ofth
e
C
on
cise
G
uide
is
design
ed
to
facilitate
com
parison
ofrelated
targets
from
m
aterialcon
tem
porary
to
m
id-2017,an
d
supersedes
data
presen
ted
in
th
e
2015/16
an
d
2013/14
C
on
cise
G
uides
an
d
previous
G
uides
to
R
eceptors
an
d
C
h
an
n
els.
It
is
produced
in
close
con
jun
ction
w
ith
th
e
N
om
en
clature
C
om
m
ittee
of
th
e
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology
(N
C
-IU
PH
A
R
),th
erefore,providin
g
officialIU
PH
A
R
classification
an
d
n
om
en
clature
for
h
um
an
drug
targets,w
h
ere
appropriate.
C
o
n
fl
ict
o
f
in
terest
Th
e
auth
ors
state
th
at
th
ere
are
n
o
con
flicts
of
in
terest
to
declare.
c⃝
2017
Th
e
A
uth
ors.British
Journ
alof
Ph
arm
acology
publish
ed
by
Joh
n
W
iley
&
Son
s
Ltd
on
beh
alf
of
British
Ph
arm
acologicalSociety.
Th
is
is
an
open
access
article
un
der
th
e
term
s
ofth
e
C
reative
C
om
m
on
s
A
ttribution
Licen
se,w
h
ich
perm
its
use,distribution
an
d
reproduction
in
an
y
m
edium
,provided
th
e
origin
alw
ork
is
properly
cited.
O
verview
:Ligan
d-gated
ion
ch
an
n
els
(LG
IC
s)are
in
tegralm
em
-
bran
e
protein
sth
atcon
tain
a
pore
w
h
ich
allow
sth
e
regulated
flow
of
selected
ion
s
across
th
e
plasm
a
m
em
bran
e.
Ion
flux
is
pas-
sive
an
d
driven
by
th
e
electroch
em
ical
gradien
t
for
th
e
perm
e-
an
t
ion
s.
Th
ese
ch
an
n
els
are
open
,
or
gated,
by
th
e
bin
din
g
of
a
n
eurotran
sm
itterto
an
orth
osteric
site(s)th
attriggers
a
con
form
a-
tion
alch
an
ge
th
at
results
in
th
e
con
ductin
g
state.
M
odulation
of
gatin
g
can
occur
by
th
e
bin
din
g
of
en
dogen
ous,
or
exogen
ous,
m
odulators
to
allosteric
sites.
LG
IC
s
m
ediate
fast
syn
aptic
tran
s-
m
ission
,on
a
m
illisecon
d
tim
e
scale,in
th
e
n
ervous
system
an
d
at
th
e
som
atic
n
eurom
uscular
jun
ction
.
Such
tran
sm
ission
in
volves
th
e
release
ofa
n
eurotran
sm
itter
from
a
pre-syn
aptic
n
euron
e
an
d
th
e
subsequen
t
activation
of
post-syn
aptically
located
receptors
th
at
m
ediate
a
rapid,
ph
asic,
electrical
sign
al
(th
e
excitatory,
or
in
h
ibitory,post-syn
aptic
poten
tial).H
ow
ever,in
addition
to
th
eir
tradition
alrole
in
ph
asic
n
eurotran
sm
ission
,it
is
n
ow
establish
ed
th
atsom
e
LG
IC
s
m
ediate
a
ton
ic
form
ofn
euron
alregulation
th
at
results
from
th
e
activation
ofextra-syn
aptic
receptors
by
am
bien
t
levels
ofn
eurotran
sm
itter.Th
e
expression
ofsom
e
LG
IC
s
by
n
on
-
excitable
cells
is
suggestive
of
addition
alfun
ction
s.
By
con
ven
tion
,
th
e
LG
IC
s
com
prise
th
e
excitatory,
cation
-
selective,
n
icotin
ic
acetylch
olin
e
[54,
257],
5-H
T3
[21,
386],
ion
otropic
glutam
ate
[231,365]an
d
P2X
receptors
[174,349]an
d
th
e
in
h
ibitory,
an
ion
-selective,
G
A
BA
A
[27,
287]
an
d
glycin
e
re-
ceptors
[233,
399].
Th
e
n
icotin
ic
acetylch
olin
e,
5-H
T3,
G
A
BA
A
an
d
glycin
e
receptors
(an
d
an
addition
al
zin
c-activated
ch
an
n
el)
are
pen
tam
eric
structuresan
d
are
frequen
tly
referred
to
asth
e
C
ys-
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w
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loop
receptors
due
to
th
e
presen
ce
of
a
defin
in
g
loop
of
residues
form
ed
by
a
disulph
ide
bon
d
in
th
e
extracellular
dom
ain
of
th
eir
con
stituen
t
subun
its
[259,353].
H
ow
ever,th
e
prokaryotic
an
ces-
tors
of
th
ese
receptors
con
tain
n
o
such
loop
an
d
th
e
term
pen
-
tam
eric
ligan
d-gated
ion
ch
an
n
el(pLG
IC
)isgain
in
g
acceptan
ce
in
th
e
literature
[145].
Th
e
ion
otropic
glutam
ate
an
d
P2X
receptors
are
tetram
eric
an
d
trim
eric
structures,respectively.M
ultiple
gen
es
en
code
th
e
subun
its
of
LG
IC
s
an
d
th
e
m
ajority
of
th
ese
receptors
are
h
eterom
ultim
ers.Such
com
bin
ation
aldiversity
results,w
ith
in
each
classofLG
IC
,in
a
w
ide
ran
ge
ofreceptorsw
ith
differin
g
ph
ar-
m
acologicalan
d
bioph
ysicalpropertiesan
d
varyin
g
pattern
sofex-
pression
w
ith
in
th
e
n
ervous
system
an
d
oth
er
tissues.
Th
e
LG
IC
s
th
us
presen
tattractive
targets
for
n
ew
th
erapeutic
agen
ts
w
ith
im
-
proved
discrim
in
ation
betw
een
receptor
isoform
s
an
d
a
reduced
propen
sity
for
off-target
effects.Th
e
developm
en
t
of
n
ovel,faster
screen
in
g
tech
n
iques
for
com
poun
ds
actin
g
on
LG
IC
s
[100]
w
ill
greatly
aid
in
th
e
developm
en
t
of
such
agen
ts.
Fam
ily
stru
ctu
re
S131
5-H
T
3
receptors
S133
A
cid-sen
sin
g
(proton
-gated)
ion
ch
an
n
els
(A
SIC
s)
S135
Epith
elialsodium
ch
an
n
els
(EN
aC
)
S137
G
A
BA
A
receptors
S142
G
lycin
e
receptors
S144
Ion
otropic
glutam
ate
receptors
S149
IP
3
receptor
S150
N
icotin
ic
acetylch
olin
e
receptors
S154
P2X
receptors
S156
ZA
C
5-H
T
3
receptors
Ligan
d-gated
ion
ch
an
n
els→
5-H
T
3
receptors
O
verview
:
Th
e
5-H
T
3
receptor
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
5-H
yd
ro
x
ytryp
tam
in
e
(sero
to
n
in
)
recep
to
rs
[157])
is
a
ligan
d-gated
ion
ch
an
n
el
of
th
e
C
ys-loop
fam
ily
th
at
in
cludes
th
e
zin
c-activated
ch
an
n
els,
n
icotin
ic
acetylch
olin
e,
G
A
BA
A
an
d
strych
n
in
e-sen
sitive
glycin
e
receptors.Th
e
receptor
exists
as
a
pen
tam
er
of
4TM
subun
its
th
at
form
an
in
trin
sic
cation
selective
ch
an
n
el
[21].
Five
h
um
an
5-
H
T
3
receptor
subun
its
h
ave
been
clon
ed
an
d
h
om
o-oligom
eric
as-
sem
blies
of
5-H
T
3 A
an
d
h
etero-oligom
eric
assem
blies
of
5-H
T
3 A
an
d
5-H
T
3 B
subun
its
h
ave
been
ch
aracterised
in
detail.
Th
e
5-
H
T
3 C
(H
T
R3C
,Q
8W
X
A
8),5-H
T
3 D
(H
T
R3D
,Q
70Z44)an
d
5-H
T
3 E
(H
T
R3E,
A
5X
5Y
0)
subun
its
[189,
277],
like
th
e
5-H
T
3 B
subun
it,
do
n
ot
form
fun
ction
al
h
om
om
ers,
but
are
reported
to
assem
ble
w
ith
th
e
5-H
T
3 A
subun
it
to
in
fluen
ce
its
fun
ction
al
expression
rath
er
th
an
ph
arm
acological
profile
[148,279,379].
5-H
T
3 A
,-C
,
-D
,an
d
-E
subun
its
also
in
teract
w
ith
th
e
ch
aperon
e
R
IC
-3
w
h
ich
predom
in
an
tly
en
h
an
ces
th
e
surface
expression
of
h
om
om
eric
5-
H
T
3 A
receptor
[379].
Th
e
co-expression
of
5-H
T
3 A
an
d
5-H
T
3 C
-E
subun
its
h
as
been
dem
on
strated
in
h
um
an
colon
[186].A
recom
-
bin
an
t
h
etero-oligom
eric
5-H
T
3 A
B
receptor
h
as
been
reported
to
con
tain
tw
o
copies
ofth
e
5-H
T
3 A
subun
it
an
d
th
ree
copies
ofth
e
5-H
T
3 B
subun
itin
th
e
orderB-B-A
-B-A
[25],butth
isisin
con
sisten
t
w
ith
recen
t
reports
w
h
ich
sh
ow
at
least
on
e
A
-A
in
terface
[225,
357].
Th
e
5-H
T
3 B
subun
it
im
parts
distin
ctive
bioph
ysical
prop-
erties
upon
h
etero-oligom
eric
5-H
T
3 A
B
versus
h
om
o-oligom
eric
5-H
T
3 A
recom
bin
an
t
receptors
[77,98,135,176,194,301,344],
in
fluen
ces
th
e
poten
cy
ofch
an
n
elblockers,butgen
erally
h
as
on
ly
a
m
odesteffectupon
th
e
apparen
taffin
ity
ofagon
ists,orth
e
affin
-
ity
of
an
tagon
ists
([41],
but
see
[76,
81,
98])
w
h
ich
m
ay
be
ex-
plain
ed
by
th
e
orth
osteric
bin
din
g
site
residin
g
at
an
in
terface
form
ed
betw
een
5-H
T
3 A
subun
its
[225,
357].
H
ow
ever,
5-H
T
3 A
an
d
5-H
T
3 A
B
receptors
differin
th
eirallosteric
regulation
by
som
e
gen
eral
an
aesth
etic
agen
ts,sm
all
alcoh
ols
an
d
in
doles
[158,317,
341].
Th
e
poten
tial
diversity
of
5-H
T
3
receptors
is
in
creased
by
altern
ative
splicin
g
of
th
e
gen
es
H
TR
3 A
an
d
E
[44,151,276,278,
279].
In
addition
,th
e
use
of
tissue-specific
prom
oters
drivin
g
ex-
pression
from
differen
ttran
scription
alstartsitesh
asbeen
reported
for
th
e
H
T
R3A
,H
T
R3B,H
T
R3D
an
d
H
T
R3E
gen
es,w
h
ich
could
re-
sult
in
5-H
T
3
subun
its
h
arbourin
g
differen
t
N
-term
in
i
[176,
276,
366].To
date,in
clusion
ofth
e
5-H
T
3 A
subun
itappears
im
perative
for
5-H
T
3
receptor
fun
ction
.
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
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FullC
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N
om
enclature
5-H
T
3 AB
5-H
T
3 A
Subunits
5-H
T
3 A,5-H
T
3 B
5-H
T
3 A
Selective
agonists
–
m
eta-chlorphenylbiguanide
[26,77,214,262,263],2-m
ethyl-5-H
T
[26,77,214,
262],SR57227A
[102]–
Rat,1-phenylbiguanide
[26]
Antagonists
–
vortioxetine
(pK
i 8.4)
[18],m
etoclopram
ide
(pK
i 6–6.4)
[41,152]
Selective
antagonists
–
palonosetron
(pK
i 10.5)
[269],alosetron
(pK
i 9.5)
[146],(S)-zacopride
(pK
i 9)
[41],
granisetron
(pK
i ∼
8.6–8.8)
[152,262],tropisetron
(pK
i 8.5–8.8)
[214,262],
ondansetron
(pK
i ∼
7.8–8.3)
[41,152,262]
C
hannelblockers
picrotoxinin
(pIC
50
4.2)
[352],bilobalide
(pIC
50
2.5)
[352],ginkgolide
B
(pIC
50
2.4)
[352]
picrotoxinin
(pIC
50
5)
[351],TM
B-8
(pIC
50
4.9)
[348],diltiazem
(pIC
50
4.7)
[351],
bilobalide
(pIC
50
3.3)
[351],ginkgolide
B
(pIC
50
3.1)
[351]
Labelled
ligands
–
[ 3H
]ram
osetron
(Antagonist)
(pK
d
9.8)
[262],[ 3H
]G
R65630
(Antagonist)
(pK
d
8.6–9.3)
[146,214],[ 3H
]granisetron
(Antagonist)
(pK
d
8.9)
[41,152],
[ 3H
](S)-zacopride
(Antagonist)
(pK
d
8.7)
[293],[ 3H
]LY278584
(Antagonist)
(pK
d
8.5)
[1]
FunctionalC
haracteristics
γ
=
0.4-0.8
pS
[+
5-H
T3B,γ
=
16
pS];inw
ardly
rectifying
current
[+
5-H
T3B,
rectification
reduced];n
H
2-3
[+
5-H
T3B
1-2];relative
perm
eability
to
divalent
cations
reduced
by
co-expression
ofthe
5-H
T3B
subunit
γ
=
0.4-0.8
pS
[+
5-H
T3B,γ
=
16
pS];inw
ardly
rectifying
current
[+
5-H
T3B,
rectification
reduced];n
H
2-3
[+
5-H
T3B
1-2];relative
perm
eability
to
divalent
cations
reduced
by
co-expression
ofthe
5-H
T3B
subunit
Subunits
N
om
enclature
5-H
T3A
5-H
T3B
5-H
T3C
5-H
T3D
5-H
T3E
H
G
N
C
,U
niProt
H
TR3A,P46098
H
TR3B,O
95264
H
TR3C,Q
8W
X
A8
H
TR3D
,Q
70Z44
H
TR3E,A5X
5Y0
FunctionalC
haracteristics
γ
=
0.4-0.8
pS
[+
5-H
T3B,γ
=
16
pS];inw
ardly
rectifying
current
[+
5-H
T3B,rectification
reduced];
n
H
2-3
[+
5-H
T3B
1-2];relative
perm
eability
to
divalent
cations
reduced
by
co-expression
ofthe
5-H
T3B
subunit
γ
=
0.4-0.8
pS
[+
5-H
T3B,γ
=
16
pS];inw
ardly
rectifying
current
[+
5-H
T3B,rectification
reduced];
n
H
2-3
[+
5-H
T3B
1-2];relative
perm
eability
to
divalent
cations
reduced
by
co-expression
ofthe
5-H
T3B
subunit
–
–
–
C
o
m
m
en
ts:
Q
uan
titative
data
in
th
e
table
refer
to
h
om
o-
oligom
eric
assem
blies
of
th
e
h
um
an
5-H
T
3 A
subun
it,
or
th
e
re-
ceptor
n
ative
to
h
um
an
tissues.
Sign
ifican
t
ch
an
ges
in
troduced
by
co-expression
ofth
e
5-H
T
3 B
subun
itare
in
dicated
in
paren
th
e-
sis.A
lth
ough
n
ota
selective
an
tagon
ist,m
eth
adon
e
displays
m
ul-
tim
odal
an
d
subun
it-depen
den
t
an
tagon
ism
of
5-H
T
3
receptors
[81].
Sim
ilarly,
TM
B-8,
diltiazem
,
picrotoxin
,
bilobalide
an
d
gin
kgolide
B
are
n
ot
selective
for
5-H
T
3
receptors
(e.g.[352]).
Th
e
an
ti-m
alarialdrugsm
efloquin
e
an
d
quin
in
e
exerta
m
odestly
m
ore
poten
t
block
of
5-H
T
3 A
versus
5-H
T
3 A
B
receptor-m
ediated
re-
spon
ses[354].K
n
ow
n
betterasa
partialagon
istofn
icotin
ic
acetyl-
ch
olin
e
α
4β2
receptors,
varen
iclin
e
is
also
an
agon
ist
of
th
e
5-
H
T
3 A
receptor
[231].
H
um
an
[26,
262],
rat
[164],
m
ouse
[243],
guin
ea-pig
[214]ferret[264]an
d
can
in
e
[178]orth
ologuesofth
e
5-
H
T
3 A
receptor
subun
it
h
ave
been
clon
ed
th
at
exh
ibit
in
traspecies
variation
s
in
receptor
ph
arm
acology.
N
otably,
m
ost
ligan
ds
dis-
play
sign
ifican
tly
reduced
affin
ities
atth
e
guin
ea-pig
5-H
T
3
recep-
tor
in
com
parison
w
ith
oth
er
species.
In
addition
to
th
e
agen
ts
listed
in
th
e
table,
n
ative
an
d
recom
bin
an
t
5-H
T
3
receptors
are
subject
to
allosteric
m
odulation
by
extracellular
divalen
t
cation
s,
alcoh
ols,severalgen
eralan
aesth
etics
an
d
5-h
ydroxy-
an
d
h
alide-
substituted
in
doles
(see
review
s
[294,355,356,380]).
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Fu
rth
er
read
in
g
o
n
5-H
T
3
recep
to
rs
A
n
drew
s,
PL
et
al.
(2014)
N
ausea
an
d
th
e
quest
for
th
e
perfect
an
ti-em
etic.
Eur
J
Pharm
acol
722
:
108-21
[PM
ID
:24157981]
Fakh
fouri,
G
et
al.
(2015)
From
C
h
em
oth
erapy-In
duced
Em
esis
to
N
europrotection
:
Th
erapeutic
O
pportun
ities
for
5-H
T3
R
eceptor
A
n
tagon
ists.M
olN
eurobiol
52
:1670-1679
[PM
ID
:25377794]
G
upta,D
et
al.
(2016)
5H
T3
receptors:
Target
for
n
ew
an
tidepressan
t
drugs.
N
eurosciBiobehav
Rev
64
:311-25
[PM
ID
:26976353]
H
oyer,
D
et
al.
(1994)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology
classification
of
receptors
for
5-
h
ydroxytryptam
in
e
(Seroton
in
).
Pharm
acolRev
46
:157-203
Loch
n
er,
M
et
al.
(2015)
A
review
of
fluorescen
t
ligan
ds
for
studyin
g
5-H
T3
receptors.
N
europhar-
m
acology
98
:31-40
[PM
ID
:25892507]
R
ojas,C
et
al.
(2014)
M
olecular
m
ech
an
ism
s
of
5-H
T(3)
an
d
N
K
(1)
receptor
an
tagon
ists
in
preven
-
tion
of
em
esis.Eur
JPharm
acol722
:26-37
[PM
ID
:24184669]
Acid-sensing
(proton-gated)
ion
channels
(ASIC
s)
Ligan
d-gated
ion
ch
an
n
els→
A
cid-sen
sin
g
(proton
-gated)
ion
ch
an
n
els
(A
SIC
s)
O
verview
:A
cid-sen
sin
g
ion
ch
an
n
els(A
SIC
s,n
o
m
en
clatu
re
as
ag
reed
b
y
N
C
-IU
P
H
A
R
[193])
are
m
em
bers
of
a
N
a +
ch
an
n
el
superfam
ily
th
at
in
cludes
th
e
epith
elialN
a +
ch
an
n
el(EN
aC
),th
e
FM
R
F-am
ide
activated
ch
an
n
el
(FaN
aC
)
of
in
vertebrates,
th
e
de-
gen
erin
s
(D
EG
)
of
C
aenorhabitis
elegans,
ch
an
n
els
in
D
rosophila
m
elanogaster
an
d
’orph
an
’
ch
an
n
els
th
at
in
clude
BLIN
aC
[325]
an
d
IN
aC
[323]
th
at
h
ave
also
been
n
am
ed
BA
SIC
s,for
bile
acid-
activated
ion
ch
an
n
els
[383].
A
SIC
subun
its
con
tain
tw
o
TM
do-
m
ain
s
an
d
assem
ble
as
h
om
o-
or
h
etero-trim
ers
[17,
125,
175]
to
form
proton
-gated,
voltage-in
sen
sitive,
N
a +
perm
eable,
ch
an
-
n
els
(review
ed
in
[131,382]).
Splice
varian
ts
of
A
SIC
1
[provision
-
ally
term
ed
A
SIC
1a
(A
SIC
,A
SIC
α
,BN
aC
2α
)[376],A
SIC
1b
(A
SIC
β,
BN
aC
2β)
[61]
an
d
A
SIC
1b2
(A
SIC
β2)
[367];
n
ote
th
at
A
SIC
1a
is
also
perm
eable
to
C
a 2+]
an
d
A
SIC
2
[provision
ally
term
ed
A
SIC
2a
(M
D
EG
1,BN
aC
1α
,BN
C
1α
)
[121,308,377]an
d
A
SIC
2b
(M
D
EG
2,
BN
aC
1β)[223]]h
ave
been
clon
ed.U
n
like
A
SIC
2a
(listed
in
table),
h
eterologous
expression
of
A
SIC
2b
alon
e
does
n
ot
support
H
+-
gated
curren
ts.
A
th
ird
m
em
ber,
A
SIC
3
(D
R
A
SIC
,
TN
aC
1)
[375],
h
as
been
iden
tified.
A
fourth
m
am
m
alian
m
em
ber
of
th
e
fam
ily
(A
SIC
4/SPA
SIC
)
does
n
ot
support
a
proton
-gated
ch
an
n
el
in
h
et-
erologous
expression
system
s
an
d
is
reported
to
dow
n
regulate
th
e
expression
of
A
SIC
1a
an
d
A
SIC
3
[1,
92,
130,
222].
A
SIC
ch
an
-
n
els
are
prim
arily
expressed
in
cen
tralan
d
periph
eraln
euron
s
in
-
cludin
g
n
ociceptors
w
h
ere
th
ey
participate
in
n
euron
alsen
sitivity
to
acidosis.
Th
ey
h
ave
also
been
detected
in
taste
receptor
cells
(A
SIC
1-3),
ph
otoreceptors
an
d
retin
al
cells
(A
SIC
1-3),
coch
lear
h
air
cells
(A
SIC
1b),testis
(h
A
SIC
3),pituitary
glan
d
(A
SIC
4),lun
g
epith
elial
cells
(A
SIC
1a
an
d
-3),
uroth
elial
cells,
adipose
cells
(A
SIC
3),
vascular
sm
ooth
m
uscle
cells
(A
SIC
1-3),
im
m
un
e
cells
(A
SIC
1,-3
an
d
-4)
an
d
bon
e
(A
SIC
1-3).
A
n
eurotran
sm
itter-like
fun
ction
of
proton
s
h
as
been
suggested,
in
volvin
g
postsyn
apti-
cally
located
A
SIC
s
of
th
e
C
N
S
in
fun
ction
s
such
as
learn
in
g
an
d
fear
perception
[97,
207,
408],
respon
ses
to
focal
isch
em
ia
[390]
an
d
autoim
m
un
e
in
flam
m
ation
[115],asw
ellasseizures[408]an
d
pain
[37,
84,
85,
89].
H
eterologously
expressed
h
eterom
ultim
ers
form
ion
ch
an
n
els
w
ith
differen
ces
in
kin
etics,ion
selectivity,pH
-
sen
sitivity
an
d
sen
sitivity
to
blockers
th
at
resem
ble
som
e
of
th
e
n
ative
proton
activated
curren
ts
recorded
from
n
euron
es
[15,24,
107,223].
N
om
enclature
ASIC
1
ASIC
2
H
G
N
C
,U
niProt
ASIC1,P78348
ASIC2,Q
16515
Endogenous
activators
Extracellular
H
+
(ASIC
1a)
(pEC
50 ∼
6.2–6.8),Extracellular
H
+
(ASIC
1b)
(pEC
50 ∼
5.1–6.2)
Extracellular
H
+
(pEC
50 ∼
4.1–5)
C
hannelblockers
psalm
otoxin
1
(ASIC
1a)
(pIC
50
9),Zn
2+
(ASIC
1a)
(pIC
50 ∼
8.2),Pb
2+
(ASIC
1b)
(pIC
50 ∼
5.8),
A-317567
(ASIC
1a)
(pIC
50 ∼
5.7)
[99]–
Rat,Pb
2+
(ASIC
1a)
(pIC
50 ∼
5.4),am
iloride
(ASIC
1a)
(pIC
50
5),benzam
il(ASIC
1a)
(pIC
50
5),ethylisopropylam
iloride
(ASIC
1a)
(pIC
50
5),nafam
ostat
(ASIC
1a)
(pIC
50 ∼
4.9),am
iloride
(ASIC
1b)
(pIC
50
4.6–4.7),flurbiprofen
(ASIC
1a)
(pIC
50
3.5)
[372]–
Rat,
ibuprofen
(ASIC
1a)
(pIC
50 ∼
3.5),N
i 2+
(ASIC
1a)
(pIC
50 ∼
3.2)
am
iloride
(pIC
50
4.6),A-317567
(pIC
50 ∼
4.5),nafam
ostat
(pIC
50 ∼
4.2),
C
d
2+
(pIC
50 ∼
3)
Labelled
ligands
[ 125I]psalm
otoxin
1
(ASIC
1a)
(pK
d
9.7)
–
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(continued)
N
om
enclature
ASIC
1
ASIC
2
FunctionalC
haracteristics
A
SIC
1a:γ˜14pS
P
N
a /P
K
=
5-13,P
N
a /P
C
a
=2.5
rapid
activation
rate
(5.8-13.7
m
s),rapid
inactivation
rate
(1.2-4
s)
@
pH
6.0,slow
recovery
(5.3-13s)
@
pH
7.4
A
SIC
1b
:γ˜19
pS
P
N
a /P
K
=14.0,P
N
a ≫
P
C
a
rapid
activation
rate
(9.9
m
s),rapid
inactivation
rate
(0.9-1.7
s)
@
pH
6.0,slow
recovery
(4.4-7.7
s)
@
pH
7.4
γ˜10.4-13.4
pS
P
N
a /P
K
=10,P
N
a /P
C
a
=
20
rapid
activation
rate,m
oderate
inactivation
rate
(3.3-5.5
s)
@
pH
5
C
om
m
ents
ASIC
1a
and
ASIC
1b
are
also
blocked
by
diarylam
idines
(IC
50 ˜3
µ
M
for
ASIC
1a)
ASIC
2
is
also
blocked
by
diarylam
idines
N
om
enclature
ASIC
3
H
G
N
C
,U
niProt
ASIC3,Q
9U
H
C
3
Endogenous
activators
Extracellular
H
+
(transient
com
ponent)
(pEC
50 ∼
6.2–6.7),Extracellular
H
+
(sustained
com
ponent)
(pEC
50 ∼
3.5–4.3)
Activators
G
M
Q
(largly
non-desensitizing;at
pH
7.4)
(pEC
50 ∼
3),arcaine
(at
pH
7.4)
(pEC
50 ∼
2.9),agm
atine
(at
pH
7.4)
(pEC
50 ∼
2)
C
hannelblockers
APETx2
(transient
com
ponent
only)
(pIC
50
7.2),nafam
ostat
(transient
com
ponent)
(pIC
50 ∼
5.6),A-317567
(pIC
50 ∼
5),am
iloride
(transient
com
ponent
only
-sustained
com
ponent
enhanced
by
200µ
M
am
iloride
at
pH
4)
(pIC
50
4.2–4.8),G
d
3+
(pIC
50
4.4),Zn
2+
(pIC
50
4.2),aspirin
(sustained
com
ponent)
(pIC
50
4)
[372],diclofenac
(sustained
com
ponent)
(pIC
50
4),salicylic
acid
(sustained
com
ponent)
(pIC
50
3.6)
FunctionalC
haracteristics
γ˜13-15
pS;
biphasic
response
consisting
ofrapidly
inactivating
transient
and
sustained
com
ponents;
very
rapid
activation
(<
5
m
s)
and
inactivation
(0.4
s);
fast
recovery
(0.4-0.6
s)
@
pH
7.4,transient
com
ponent
partially
inactivated
at
pH
7.2
C
om
m
ents
ASIC
3
is
also
blocked
by
diarylam
idines
C
o
m
m
en
ts:
psalm
otoxin
1
(PcTx1)
in
h
ibits
A
SIC
1a
by
in
creas-
in
g
th
e
affin
ity
to
H
+
an
d
prom
otin
g
ch
an
n
eldesen
sitization
[64,
107].
PcTx1
h
as
little
effect
on
A
SIC
2a,
A
SIC
3
or
A
SIC
1a
ex-
pressed
as
a
h
eterom
ultim
er
w
ith
eith
er
A
SIC
2a,
or
A
SIC
3
but
does
in
h
ibit
A
SIC
1a
expressed
as
a
h
eterom
ultim
er
w
ith
A
SIC
2b
[330].
A
SIC
1-con
tain
in
g
h
om
o-
an
d
h
eterom
ers
are
in
h
ibited
by
M
am
balgin
s,
toxin
s
con
tain
ed
in
th
e
black
m
am
ba
ven
om
,
w
h
ich
in
duce
in
A
SIC
1a
an
acidic
sh
ift
of
th
e
pH
depen
den
ce
of
activation
[89].
A
PETx2
m
ost
poten
tly
blocks
h
om
om
eric
A
SIC
3
ch
an
n
els,
but
also
A
SIC
2b+A
SIC
3,
A
SIC
1b+A
SIC
3,
an
d
A
SIC
1a+A
SIC
3
h
eterom
eric
ch
an
n
els
w
ith
IC
50
values
of117
n
M
,
900
n
M
an
d
2
µ
M
,respectively.A
PETx2
h
as
n
o
effect
on
A
SIC
1a,
A
SIC
1b,
A
SIC
2a,
or
A
SIC
2a+A
SIC
3
[88,
90].
A
PETx2
in
h
ibits
h
ow
ever
also
voltage-gated
N
a+
ch
an
n
els
[34,
297].
IC
50
val-
ues
for
A
-317567
are
in
ferred
from
blockade
of
A
SIC
ch
an
n
els
n
ative
to
dorsal
root
gan
glion
n
euron
es
[99].
Th
e
pEC
50
val-
ues
for
proton
activation
of
A
SIC
ch
an
n
els
are
in
fluen
ced
by
n
u-
m
erous
factors
in
cludin
g
extracellular
di-
an
d
poly-valen
t
ion
s,
Zn
2+,
protein
kin
ase
C
an
d
serin
e
proteases
(review
ed
in
[193,
382]).
R
apid
acidification
is
required
for
activation
of
A
SIC
1
an
d
A
SIC
3
due
to
fast
in
activation
/desen
sitization
.
pEC
50
values
for
H
+-activation
of
eith
er
tran
sien
t,or
sustain
ed,curren
ts
m
ediated
by
A
SIC
3
vary
in
th
e
literature
an
d
m
ay
reflect
species
an
d/or
m
eth
odologicaldifferen
ces
[16,79,375].
Th
e
tran
sien
t
A
SIC
cur-
ren
t
com
pon
en
t
is
N
a +-selective
(PN
a/PK
of
about
10)
[375,392]
w
h
ereas
th
e
sustain
ed
curren
t
com
pon
en
t
th
at
is
observed
w
ith
A
SIC
3
an
d
som
e
A
SIC
h
eterom
ers
is
n
on
-selective
betw
een
N
a +
an
d
K
+
[79].
Th
e
reducin
g
agen
ts
dith
ioth
reitol
(D
TT)
an
d
glu-
tath
ion
e
(G
SH
)
in
crease
A
SIC
1a
curren
ts
expressed
in
C
H
O
cells
an
d
A
SIC
-like
curren
ts
in
sen
sory
gan
glia
an
d
cen
tral
n
euron
s
[8,
68]
w
h
ereas
oxidation
,
th
rough
th
e
form
ation
of
in
tersub-
un
itdisulph
ide
bon
ds,reducescurren
tsm
ediated
by
A
SIC
1a
[405].
A
SIC
1a
is
also
irreversibly
m
odulated
by
extracellular
serin
e
pro-
teases,
such
as
trypsin
,
th
rough
proteolytic
cleavage
[373].
N
on
-
steroidal
an
ti-in
flam
m
atory
drugs
(N
SA
ID
s)
are
direct
in
h
ibitors
ofA
SIC
curren
ts
(review
ed
in
[22]).Extracellular
Zn
2+
poten
tiates
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w
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proton
activation
ofh
om
om
eric
an
d
h
eterom
eric
ch
an
n
els
in
cor-
poratin
g
A
SIC
2a,
but
n
ot
h
om
om
eric
A
SIC
1a
or
A
SIC
3
ch
an
n
els
[23].
H
ow
ever,
rem
oval
of
con
tam
in
atin
g
Zn
2+
by
ch
elation
re-
veals
a
h
igh
affin
ity
block
ofh
om
om
eric
A
SIC
1a
an
d
h
eterom
eric
A
SIC
1a+A
SIC
2
ch
an
n
els
by
Zn
2+
in
dicatin
g
com
plex
biph
asic
ac-
tion
s
of
th
e
divalen
t
[69].
N
itric
oxide
poten
tiates
subm
axim
al
curren
ts
activated
by
H
+
m
ediated
by
A
SIC
1a,
A
SIC
1b,
A
SIC
2a
an
d
A
SIC
3
[47].
A
m
m
on
ium
ion
s
activate
A
SIC
ch
an
n
els
(m
ost
likely
A
SIC
1a)
in
m
idbrain
dopam
in
ergic
n
euron
es:
th
at
m
ay
be
relevan
t
to
n
euron
aldisorders
associated
w
ith
h
yperam
m
on
e-
m
ia
[302].
Th
e
positive
m
odulation
of
h
om
om
eric,
h
eterom
eric
an
d
n
ative
A
SIC
ch
an
n
els
by
th
e
peptide
FM
R
Fam
ide
an
d
re-
lated
substan
ces,
such
as
n
europeptides
FF
an
d
SF,
is
review
ed
in
detail
in
[369].
In
flam
m
atory
con
dition
s
an
d
particular
pro-
in
flam
m
atory
m
ediators
such
as
arach
idon
ic
acid
in
duce
overex-
pression
of
A
SIC
-en
codin
g
gen
es
an
d
en
h
an
ce
A
SIC
curren
ts
[85,
241,337].
Th
e
sustain
ed
curren
t
com
pon
en
t
m
ediated
by
A
SIC
3
is
poten
tiated
by
h
yperton
ic
solution
s
in
a
m
an
n
er
th
at
is
syn
er-
gistic
w
ith
th
e
effect
of
arach
idon
ic
acid
[85].
A
SIC
3
is
partially
activated
by
th
e
lipids
lysoph
osph
atidylch
olin
e
(LPC
)an
d
arach
i-
don
ic
acid
[244].
M
it-Toxin
,w
h
ich
is
con
tain
ed
in
th
e
ven
om
of
th
e
Texas
coralsn
ake,activates
severalA
SIC
subtypes
[37].
Selec-
tive
activation
ofA
SIC
3
by
G
M
Q
ata
site
separate
from
th
e
proton
bin
din
g
site
is
poten
tiated
by
m
ild
acidosis
an
d
reduced
extracel-
lular
C
a 2+
[402].
Fu
rth
er
read
in
g
o
n
A
cid
-sen
sin
g
(p
ro
to
n
-g
ated
)
io
n
ch
an
n
els
(A
SIC
s)
Baron
A
et
al.
(2015)
Ph
arm
acology
of
acid-sen
sin
g
ion
ch
an
n
els
-
Ph
ysiologicalan
d
th
erapeutical
perspectives.
N
europharm
acology
94
:19-35
[PM
ID
:25613302]
Boscardin
E
et
al.
(2016)
Th
e
fun
ction
an
d
regulation
of
acid-sen
sin
g
ion
ch
an
n
els
(A
SIC
s)
an
d
th
e
epith
elial
N
a(+)
ch
an
n
el
(EN
aC
):
IU
PH
A
R
R
eview
19.
Br
J
Pharm
acol
173
:
2671-701
[PM
ID
:27278329]
G
run
der
S
et
al.
(2015)
Bioph
ysical
properties
of
acid-sen
sin
g
ion
ch
an
n
els
(A
SIC
s).
N
europharm
a-
cology
94
:9-18
[PM
ID
:25585135]
K
ellen
berger
S
et
al.
(2015)
In
tern
ation
al
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology.
X
C
I.
struc-
ture,fun
ction
,an
d
ph
arm
acology
ofacid-sen
sin
g
ion
ch
an
n
els
an
d
th
e
epith
elialN
a+
ch
an
n
el.
Pharm
acolRev
67
:1-35
[PM
ID
:25287517]
O
sm
akov
D
I
et
al.
(2014)
A
cid-sen
sin
g
ion
ch
an
n
els
an
d
th
eir
m
odulators.
Biochem
istry
(M
osc)79
:
1528-45
[PM
ID
:25749163]
Epithelialsodium
channels
(EN
aC
)
Ligan
d-gated
ion
ch
an
n
els→
Epith
elialsodium
ch
an
n
els
(EN
aC
)
O
verview
:
Th
e
epith
elial
sodium
ch
an
n
els
(EN
aC
)
m
ediate
sodium
reabsorption
in
th
e
aldosteron
e-sen
sitive
distalpartofth
e
n
eph
ron
an
d
th
e
collectin
g
duct
of
th
e
kidn
ey.
EN
aC
is
assem
-
bled
as
a
h
eterotrim
er
com
posed
of
th
ree
subun
its
α
,β,
an
d
γ
or
δ,
β,
an
d
γ
[137].
Th
ese
subun
its
con
situte
a
fam
ily
w
ith
in
th
e
EN
aC
/D
egen
erin
super-fam
ily
[137].
G
en
es
en
codin
g
EN
aC
sub-
un
its
are
foun
d
in
allvertebrates
w
ith
th
e
exception
ofray-fin
n
ed
fish
es
[137].
EN
aC
com
posed
of
α
,
β,
an
d
γ
subun
its
is
located
m
ostly
in
tigh
t
or
h
igh
-resistan
ce
epith
elial
tissues
such
as
th
e
airw
ays,
distal
colon
an
d
exocrin
e
glan
ds
[104].
EN
aC
activity
is
tigh
tly
regulated
in
th
e
kidn
ey
by
aldosteron
e,
an
gioten
sin
II
(A
G
T
,P01019),
vasopressin
(AV
P,P01185),
in
sulin
(IN
S,P01308)
an
d
glucocorticoids;
th
is
fin
e
regulation
of
EN
aC
is
essen
tial
to
m
ain
tain
sodium
balan
ce
betw
een
daily
in
take
an
d
urin
ary
ex-
cretion
of
sodium
,circulatin
g
volum
e
an
d
blood
pressure.
EN
aC
expression
is
also
vital
for
clearan
ce
of
foetal
lun
g
fluid,
an
d
to
m
ain
tain
air-surface-liquid
[160,
227].
Sodium
reabsorption
is
suppressed
by
th
e
‘potassium
-sparin
g’
diuretics
am
iloride
an
d
triam
teren
e.EN
aC
is
a
h
eterom
ultim
eric
ch
an
n
elm
ade
ofh
om
ol-
ogous
α
β
an
d
γ
subun
its.
Th
e
prim
ary
structure
of
th
e
α
EN
aC
subun
it
w
as
iden
tified
by
expression
clon
in
g
[48,
137];
β
an
d
γ
EN
aC
subun
its
w
ere
iden
tified
by
fun
ction
alcom
plem
en
tation
of
th
e
α
subun
it
[49,137].
Each
EN
aC
subun
it
con
tain
s
2
TM
α
h
e-
lices
con
n
ected
by
a
large
extracellularloop
an
d
sh
ortcytoplasm
ic
am
in
o-
an
d
carboxy-term
in
i.
Th
e
stoich
iom
etry
of
th
e
epith
elial
sodium
ch
an
n
elin
th
e
kidn
ey
an
d
related
epith
elia
is,by
h
om
ol-
ogy
w
ith
th
e
structurally
related
ch
an
n
elA
SIC
1a,th
ough
t
to
be
a
h
eterotrim
er
of
1α
:1β:1γ
subun
its
[125].
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N
om
enclature
EN
aC
αβγ
Subunits
EN
aC
β,EN
aC
α
,EN
aC
γ
Activators
S3969
(pEC
50
5.9)
[229]
C
hannelblockers
P552-02
(pIC
50
8.1),benzam
il(pIC
50 ∼
8),am
iloride
(pIC
50
6.7–7),triam
terene
(pIC
50 ∼
5.3)
[49,192]
FunctionalC
haracteristics
γ≈
4-5
pS,P
N
a /P
K
>
20;tonically
open
at
rest;expression
and
ion
flux
regulated
by
circulating
aldosterone-m
ediated
changes
in
gene
transcription.The
action
ofaldosterone,
w
hich
occurs
in
‘early’(1.5–3
h)
and
‘late’(6-24
hr)
phases
is
com
petitively
antagonised
by
spironolactone,its
active
m
etabolites
and
eplerenone.G
lucocorticoids
are
im
portant
functionalregulators
in
lung/airw
ays
and
this
controlis
potentiated
by
thyroid
horm
one;but
the
m
echanism
underlying
such
potentiation
is
unclear
[19,311,322].The
density
of
channels
in
the
apicalm
em
brane,and
hence
G
N
a ,can
be
controlledvia
both
serum
and
glucocorticoid-regulated
kinases
(SG
K1,2
and
3)
[80,114]and
via
cAM
P/PKA
[267];and
these
protein
kinases
appear
to
actby
inactivating
N
edd-4/2,a
ubiquitin
ligase
thatnorm
ally
targets
the
EN
aC
channelcom
plex
forinternalization
and
degradation
[35,80].EN
aC
is
constitutively
activated
by
soluble
and
m
em
brane-bound
serine
proteases,such
as
furin,prostasin
(C
AP1),plasm
in
and
elastase
[202,203,305,313,314].The
activation
of
EN
aC
by
proteases
is
blocked
by
a
protein,SPLU
N
C
1,secreted
by
the
airw
ays
and
w
hich
binds
specifically
to
EN
aC
to
prevent
its
cleavage
[120].Pharm
acologicalinhibitors
of
proteases
(e.g.cam
ostat
acting
upon
prostasin)
reduce
the
activity
ofEN
aC
[237].Phosphatidylinositides
such
as
PtIns(4,5)P
2
and
PtIns(3,4,5)P
3 )
stabilise
channelgating
probably
by
binding
to
the
β
and
γ
EN
aC
subunits,respectively
[235,307],w
hilst
C
term
inalphosphorylation
ofβ
and
γ-EN
aC
by
ERK1/2
has
been
reported
to
inhibit
the
w
ithdraw
alofthe
channelcom
plex
from
the
apicalm
em
brane
[393].This
effect
m
ay
contribute
to
the
cAM
P-m
ediated
increase
in
sodium
conductance.
Subunits
N
om
enclature
EN
aC
α
EN
aC
β
EN
aC
δ
EN
aC
γ
H
G
N
C
,U
niProt
SCN
N
1A,P37088
SCN
N
1B,P51168
SCN
N
1D
,P51172
SCN
N
1G
,P51170
C
o
m
m
en
ts:
D
ata
in
th
e
table
refer
to
th
e
αβγ
h
eterom
er.
Th
ere
are
severalh
um
an
diseases
resultin
g
from
m
utation
s
in
EN
aC
sub-
un
its
[137].Liddle’s
syn
drom
e
(in
cludin
g
features
ofsalt-sen
sitive
h
yperten
sion
an
d
h
ypokalem
ia),
is
associated
w
ith
gain
of
fun
c-
tion
m
utation
s
in
th
e
β
an
d
γ
subun
its
leadin
g
to
defective
EN
aC
ubiquitylation
an
d
in
creased
stability
of
active
EN
aC
at
th
e
cell
surface
[137,
314,
324,
343].
En
zym
es
th
at
deubiquitylate
EN
aC
in
crease
its
fun
ction
in
vivo.
Pseudoh
ypoaldosteron
ism
type
1
(PH
A
-1)can
occur
th
rough
eith
er
m
utation
s
in
th
e
gen
e
en
codin
g
th
e
m
in
eralocorticoid
receptor,
or
loss
of
fun
ction
m
utation
s
in
gen
es
en
codin
g
EN
aC
subun
its
[39,137].
R
egulation
of
EN
aC
by
ph
osph
oin
ositides
m
ay
un
derlie
in
sulin
(
IN
S,P01308)-evoked
re-
n
alN
a +
reten
tion
th
atcan
com
plicate
th
e
clin
icalm
an
agem
en
tof
type
2
diabetes
usin
g
in
sulin
-sen
sitizin
g
th
iazolidin
edion
e
drugs
[132].
Fu
rth
er
read
in
g
o
n
E
p
ith
elial
so
d
iu
m
ch
an
n
els
(E
N
aC
)
Boscardin
E
et
al.
(2016)
Th
e
fun
ction
an
d
regulation
of
acid-sen
sin
g
ion
ch
an
n
els
(A
SIC
s)
an
d
th
e
epith
elial
N
a(+)
ch
an
n
el
(EN
aC
):
IU
PH
A
R
R
eview
19.
Br
J
Pharm
acol
173
:
2671-701
[PM
ID
:27278329]
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con
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ch
an
n
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an
d
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[PM
ID
:18831683]
K
ellen
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S
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al.
(2015)
In
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U
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X
C
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struc-
ture,fun
ction
,an
d
ph
arm
acology
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sin
g
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ch
an
n
els
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d
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e
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elialN
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ch
an
n
el.
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[PM
ID
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K
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al.
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g
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an
n
els
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284
:20447-51
[PM
ID
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R
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n
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ID
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G
ABA
A
receptors
Ligan
d-gated
ion
ch
an
n
els→
G
A
BA
A
receptors
O
verview
:
Th
e
G
A
BA
A
receptor
is
a
ligan
d-gated
ion
ch
an
n
elof
th
e
C
ys-loop
fam
ily
th
at
in
cludes
th
e
n
icotin
ic
acetylch
olin
e,
5-
H
T
3
an
d
strych
n
in
e-sen
sitive
glycin
e
receptors.
G
A
BA
A
receptor-
m
ediated
in
h
ibition
w
ith
in
th
e
C
N
S
occurs
by
fast
syn
aptic
tran
sm
ission
,sustain
ed
ton
ic
in
h
ibition
an
d
tem
porally
in
term
e-
diate
even
ts
th
ath
ave
been
term
ed
‘G
A
BA
A
,slow
’[51].G
A
BA
A
re-
ceptors
exist
as
pen
tam
ers
of
4TM
subun
its
th
at
form
an
in
trin
sic
an
ion
selective
ch
an
n
el.
Sequen
ces
of
six
α
,th
ree
β,th
ree
γ,on
e
δ,th
ree
ρ
,on
e
ϵ,on
e
π
an
d
on
e
θ
G
A
BA
A
receptor
subun
its
h
ave
been
reported
in
m
am
m
als
[286,
287,
331,
333].
Th
e
π
-subun
it
is
restricted
to
reproductive
tissue.
A
ltern
atively
spliced
version
s
of
m
an
y
subun
its
exist
(e.g.
α
4-
an
d
α
6-
(both
n
ot
fun
ction
al)
α
5-,
β2-,
β3-
an
d
γ2),
alon
g
w
ith
R
N
A
editin
g
of
th
e
α
3
subun
it
[75].
Th
e
th
ree
ρ
-subun
its,
(ρ
1-3)
fun
ction
as
eith
er
h
om
o-
or
h
etero-oligom
eric
assem
blies
[60,
406].
R
eceptors
form
ed
from
ρ
-subun
its,
because
of
th
eir
distin
ctive
ph
arm
acology
th
at
in
-
cludes
in
sen
sitivity
to
bicucullin
e,
ben
zodiazepin
es
an
d
barbitu-
rates,
h
ave
som
etim
es
been
term
ed
G
A
BA
C
receptors
[406],
b
u
t
th
ey
are
classifi
ed
as
G
A
B
A
A
recep
to
rs
b
y
N
C
-IU
P
H
A
R
o
n
th
e
b
asis
o
f
stru
ctu
ral
an
d
fu
n
ctio
n
al
criteria
[20,
286,
287].
M
an
y
G
A
BA
A
receptorsubtypes
con
tain
α
-,β-an
d
γ-subun
its
w
ith
th
e
likely
stoich
iom
etry
2α
.2β.1γ
[206,
287].
It
is
th
ough
t
th
at
th
e
m
ajority
of
G
A
BA
A
receptors
h
arbour
a
sin
gle
type
ofα
-
an
d
β
-subun
it
varian
t.
Th
e
α
1β2γ2
h
etero-oligom
er
con
stitutes
th
e
largest
population
of
G
A
BA
A
receptors
in
th
e
C
N
S,
follow
ed
by
th
e
α
2β3γ2
an
d
α
3β3γ2
isoform
s.
R
eceptors
th
at
in
corporate
th
e
α
4-α
5-orα
6-subun
it,or
th
e
β1-,γ1-,γ3-,δ-,ϵ-an
d
θ
-subun
its,are
less
n
um
erous,
but
th
ey
m
ay
n
on
eth
eless
serve
im
portan
t
fun
c-
tion
s.
For
exam
ple,
extrasyn
aptically
located
receptors
th
at
con
-
tain
α
6-
an
d
δ-subun
its
in
cerebellar
gran
ule
cells,
or
an
α
4-
an
d
δ-subun
it
in
den
tate
gyrus
gran
ule
cells
an
d
th
alam
ic
n
euron
es,
m
ediate
a
ton
ic
curren
t
th
at
is
im
portan
t
for
n
euron
al
excitabil-
ity
in
respon
se
to
am
bien
t
con
cen
tration
s
of
G
A
BA
[27,109,265,
327,
338].
G
A
BA
bin
din
g
occurs
at
th
e
β+/α
-
subun
it
in
terface
an
d
th
e
h
om
ologousγ+/α
-subun
its
in
terface
creates
th
e
ben
zodi-
azepin
e
site.A
secon
d
site
forben
zodiazepin
e
bin
din
g
h
asrecen
tly
been
postulated
to
occur
atth
e
α
+/β-in
terface
([310];review
ed
by
[332]).
Th
e
particular
α
-an
d
γ-subun
it
isoform
s
exh
ibit
m
arked
effects
on
recogn
ition
an
d/or
efficacy
at
th
e
ben
zodiazepin
e
site.
Th
us,
receptors
in
corporatin
g
eith
er
α
4-
or
α
6-subun
its
are
n
ot
recogn
ised
by
‘classical’
ben
zodiazepin
es,
such
as
flun
itrazepam
(but
see
[400]).
Th
e
traffickin
g,
cell
surface
expression
,
in
tern
al-
isation
an
d
fun
ction
of
G
A
BA
A
receptors
an
d
th
eir
subun
its
are
discussed
in
detail
in
several
recen
t
review
s
[66,
166,
232,
371]
buton
e
poin
tw
orth
y
ofn
ote
isth
atreceptorsin
corporatin
g
th
e
γ2
subun
it(exceptw
h
en
associated
w
ith
α
5)clusteratth
e
postsyn
ap-
tic
m
em
bran
e
(but
m
ay
distribute
dyn
am
ically
betw
een
syn
aptic
an
d
extrasyn
aptic
location
s),
w
h
ereas
as
th
ose
in
corporatin
g
th
e
d
subun
it
appear
to
be
exclusively
extrasyn
aptic.
N
C
-IU
P
H
A
R
[20,
287]
class
th
e
G
A
BA
A
receptors
accordin
g
to
th
eirsubun
itstructure,ph
arm
acology
an
d
receptorfun
ction
.C
ur-
ren
tly,eleven
n
ative
G
A
BA
A
receptors
are
classed
as
con
clusively
iden
tified
(i.e.,α
1β2γ2,α
1βγ2,α
3βγ2,α
4βγ2,α
4β2δ,α
4β3δ,α
5βγ2,
α
6βγ2,
α
6β2δ,
α
6β3δ
an
d
ρ
)
w
ith
furth
er
receptor
isoform
s
oc-
currin
g
w
ith
h
igh
probability,
or
on
ly
ten
tatively
[286,
287].
It
is
beyon
d
th
e
scope
of
th
is
G
uide
to
discuss
th
e
ph
arm
acology
of
in
dividual
G
A
BA
A
receptor
isoform
s
in
detail;
such
in
form
a-
tion
can
be
glean
ed
in
th
e
review
s
[20,
117,
181,
206,
209,
270,
286,
287,
331]
an
d
[11,
12].
A
gen
ts
th
at
discrim
in
ate
betw
een
α
-subun
it
isoform
s
are
n
oted
in
th
e
table
an
d
addition
al
agen
ts
th
at
dem
on
strate
selectivity
betw
een
receptor
isoform
s,for
exam
-
ple
via
β-subun
it
selectivity,
are
in
dicated
in
th
e
text
below
.
Th
e
distin
ctive
agon
ist
an
d
an
tagon
ist
ph
arm
acology
of
ρ
receptors
is
sum
m
arised
in
th
e
table
an
d
addition
alaspects
are
review
ed
in
[60,182,274,406].
N
om
enclature
G
ABA
A
receptorα
1
subunit
G
ABA
A
receptorα
2
subunit
H
G
N
C
,U
niProt
G
ABRA1,P14867
G
ABRA2,P47869
Agonists
gaboxadol[G
ABA
site],isoguvacine
[G
ABA
site],isonipecotic
acid
[G
ABA
site],m
uscim
ol
[G
ABA
site],piperidine-4-sulphonic
acid
[G
ABA
site]
gaboxadol[G
ABA
site],isoguvacine
[G
ABA
site],isonipecotic
acid
[G
ABA
site],
m
uscim
ol[G
ABA
site],piperidine-4-sulphonic
acid
[G
ABA
site]
Selective
antagonists
bicuculline
[G
ABA
site],gabazine
[G
ABA
site]
bicuculline
[G
ABA
site],gabazine
[G
ABA
site]
C
hannelblockers
TBPS,picrotoxin
TBPS,picrotoxin
Endogenous
allosteric
m
odulators
5α
-pregnan-3α
-ol-20-one
(Potentiation),Zn
2+
(Inhibition),
tetrahydrodeoxycorticosterone
(Potentiation)
5α
-pregnan-3α
-ol-20-one
(Potentiation),Zn
2+
(Inhibition),
tetrahydrodeoxycorticosterone
(Potentiation)
Allosteric
m
odulators
flum
azenil[benzodiazepine
site](Antagonist)
(pK
i 9.1)
[159],clonazepam
(Positive)
(pK
i 8.9)
[309],flunitrazepam
[benzodiazepine
site](Positive)
(pK
i 8.3)
[133],diazepam
[benzodiazepine
site](Positive)
(pK
i 7.8)
[309],alprazolam
[benzodiazepine
site]
(Positive)
(pEC
50
7.4)
[5],α
3IA
[benzodiazepine
site](Inverse
agonist),α
5IA
[benzodiazepine
site](Inverse
agonist),D
M
C
M
[benzodiazepine
site](Inverse
agonist)
flum
azenil[benzodiazepine
site](Antagonist)
(pK
i 9.1)
[159],clonazepam
(Positive)
(pK
i 8.8)
[309],flunitrazepam
[benzodiazepine
site](Positive)
(pK
i 8.3)
[133],
alprazolam
[benzodiazepine
site](Positive)
(pEC
50
7.9)
[5],diazepam
[benzodiazepine
site](Positive)
(pK
i 7.8)
[309],α
3IA
[benzodiazepine
site](Inverse
agonist),α
5IA
[benzodiazepine
site](Inverse
agonist),D
M
C
M
[benzodiazepine
site](Inverse
agonist)
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w
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(continued)
N
om
enclature
G
ABA
A
receptorα
1
subunit
G
ABA
A
receptorα
2
subunit
Selective
allosteric
m
odulators
zolpidem
(Positive)
(pK
i 7.4–7.7)
[134,325],L838417
[benzodiazepine
site]
(Antagonist),ZK93426
[benzodiazepine
site](Antagonist),indiplon
[benzodiazepine
site](Fullagonist),ocinaplon
[benzodiazepine
site](Fullagonist)
L838417
[benzodiazepine
site](Partialagonist),TPA023
[benzodiazepine
site](Partial
agonist)
Labelled
ligands
[ 11C
]flum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 18F]fluoroethylflum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 35S]TBPS
[anion
channel](C
hannelblocker),[ 3H
]C
G
S8216
[benzodiazepine
site]
(Allosteric
m
odulator,M
ixed),[ 3H
]flunitrazepam
[benzodiazepine
site](Allosteric
m
odulator,Positive),[ 3H
]gabazine
[G
ABA
site](Antagonist),[ 3H
]m
uscim
ol[G
ABA
site]
(Agonist),[ 3H
]zolpidem
[benzodiazepine
site](Allosteric
m
odulator,Positive)
[ 11C
]flum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 18F]fluoroethylflum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 35S]TBPS
[anion
channel](C
hannelblocker),[ 3H
]C
G
S8216
[benzodiazepine
site]
(Allosteric
m
odulator,M
ixed),[ 3H
]flunitrazepam
[benzodiazepine
site](Allosteric
m
odulator,Fullagonist),[ 3H
]gabazine
[G
ABA
site](Antagonist),[ 3H
]m
uscim
ol[G
ABA
site](Agonist)
C
om
m
ents
Zn
2+
is
an
endogenous
allosteric
regulator
and
causes
potent
inhibition
ofreceptors
form
ed
from
binary
com
binations
ofα
and
β
subunits,incorporation
ofa
δ
orγ
subunit
causes
a
m
odest,or
pronounced,reduction
in
inhibitory
potency,respectively
[208]
Zn
2+
is
an
endogenous
allosteric
regulator
and
causes
potent
inhibition
ofreceptors
form
ed
from
binary
com
binations
ofα
and
β
subunits,incorporation
ofa
δ
orγ
subunit
causes
a
m
odest,or
pronounced,reduction
in
inhibitory
potency,respectively
[208]
N
om
enclature
G
ABA
A
receptorα
3
subunit
G
ABA
A
receptorα
4
subunit
H
G
N
C
,U
niProt
G
ABRA3,P34903
G
ABRA4,P48169
Agonists
gaboxadol[G
ABA
site],isoguvacine
[G
ABA
site],isonipecotic
acid
[G
ABA
site],m
uscim
ol
[G
ABA
site],piperidine-4-sulphonic
acid
[G
ABA
site]
gaboxadol[G
ABA
site],isoguvacine
[G
ABA
site],m
uscim
ol[G
ABA
site],
piperidine-4-sulphonic
acid
[G
ABA
site](low
efficacy)
Selective
agonists
–
isonipecotic
acid
[G
ABA
site](relatively
high
efficacy)
Selective
antagonists
bicuculline
[G
ABA
site],gabazine
[G
ABA
site]
bicuculline
[G
ABA
site],gabazine
[G
ABA
site]
C
hannelblockers
TBPS,picrotoxin
TBPS,picrotoxin
Endogenous
allosteric
m
odulators
5α
-pregnan-3α
-ol-20-one
(Potentiation),Zn
2+
(Inhibition),
tetrahydrodeoxycorticosterone
(Potentiation)
5α
-pregnan-3α
-ol-20-one
(Potentiation),Zn
2+
(Inhibition),
tetrahydrodeoxycorticosterone
(Potentiation)
Allosteric
m
odulators
flum
azenil[benzodiazepine
site](Antagonist)
(pK
i 9)
[159],clonazepam
(Positive)
(pK
i
8.7)
[309],flunitrazepam
[benzodiazepine
site](Positive)
(pK
i 7.8)
[133],diazepam
[benzodiazepine
site](Positive)
(pK
i 7.8)
[309],alprazolam
[benzodiazepine
site]
(Positive)
(pEC
50
7.2)
[5],α
5IA
[benzodiazepine
site](Inverse
agonist),D
M
C
M
[benzodiazepine
site](Inverse
agonist)
–
Selective
allosteric
m
odulators
α
3IA
[benzodiazepine
site](higher
affinity),L838417
[benzodiazepine
site](Partial
agonist),Ro19-4603
[benzodiazepine
site](Inverse
agonist),TP003
[benzodiazepine
site]
(Partialagonist),TPA023
[benzodiazepine
site](Partialagonist)
Ro15-4513
[benzodiazepine
site](Fullagonist),bretazenil[benzodiazepine
site](Full
agonist)
Searchable
database:http://w
w
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(continued)
N
om
enclature
G
ABA
A
receptorα
3
subunit
G
ABA
A
receptorα
4
subunit
Labelled
ligands
[ 11C
]flum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 18F]fluoroethylflum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 35S]TBPS
[anion
channel](C
hannelblocker),[ 3H
]C
G
S8216
[benzodiazepine
site]
(Allosteric
m
odulator,M
ixed),[ 3H
]flunitrazepam
[benzodiazepine
site](Allosteric
m
odulator,Fullagonist),[ 3H
]gabazine
[G
ABA
site](Antagonist),[ 3H
]m
uscim
ol[G
ABA
site](Agonist)
[ 11C
]flum
azenil[benzodiazepine
site](Allosteric
m
odulator,Partialagonist),
[ 18F]fluoroethylflum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 35S]TBPS
[anion
channel](C
hannelblocker),[ 3H
]C
G
S8216
[benzodiazepine
site]
(Allosteric
m
odulator,M
ixed),[ 3H
]Ro154513
[benzodiazepine
site](Allosteric
m
odulator,Fullagonist),[ 3H
]gabazine
[G
ABA
site](Antagonist),[ 3H
]m
uscim
ol
[G
ABA
site](Agonist)
C
om
m
ents
Zn
2+
is
an
endogenous
allosteric
regulator
and
causes
potent
inhibition
ofreceptors
form
ed
from
binary
com
binations
ofα
and
β
subunits,incorporation
ofa
δ
orγ
subunit
causes
a
m
odest,or
pronounced,reduction
in
inhibitory
potency,respectively
[208]
diazepam
and
flunitrazepam
are
not
active
at
this
subunit.Zn
2+
is
an
endogenous
allosteric
regulator
and
causes
potent
inhibition
ofreceptors
form
ed
from
binary
com
binations
ofα
and
β
subunits,incorporation
ofa
δ
orγ
subunit
causes
a
m
odest,
or
pronounced,reduction
in
inhibitory
potency,respectively
[208].[ 3H
]Ro154513
selectively
labelsα
4-subunit-containing
receptors
in
the
presence
ofa
saturating
concentration
ofa
’classical’benzodiazepine
(e.g.diazepam
)
N
om
enclature
G
ABA
A
receptorα
5
subunit
G
ABA
A
receptorα
6
subunit
H
G
N
C
,U
niProt
G
ABRA5,P31644
G
ABRA6,Q
16445
Agonists
gaboxadol[G
ABA
site],isoguvacine
[G
ABA
site],isonipecotic
acid
[G
ABA
site],m
uscim
ol
[G
ABA
site],piperidine-4-sulphonic
acid
[G
ABA
site]
gaboxadol[G
ABA
site],isoguvacine
[G
ABA
site],m
uscim
ol[G
ABA
site],
piperidine-4-sulphonic
acid
[G
ABA
site](low
efficacy)
Selective
agonists
–
isonipecotic
acid
[G
ABA
site](relatively
high
efficacy)
Selective
antagonists
bicuculline
[G
ABA
site],gabazine
[G
ABA
site]
bicuculline
[G
ABA
site],gabazine
[G
ABA
site]
C
hannelblockers
TBPS,picrotoxin
TBPS,picrotoxin
Endogenous
allosteric
m
odulators
5α
-pregnan-3α
-ol-20-one
(Potentiation),Zn
2+
(Inhibition),
tetrahydrodeoxycorticosterone
(Potentiation)
5α
-pregnan-3α
-ol-20-one
(Potentiation),Zn
2+
(Inhibition),
tetrahydrodeoxycorticosterone
(Potentiation)
Allosteric
m
odulators
flum
azenil[benzodiazepine
site](Antagonist)
(pK
i 9.2)
[159],flunitrazepam
[benzodiazepine
site](Positive)
(pK
i 8.3)
[137],alprazolam
[benzodiazepine
site]
(Positive)
(pEC
50
8)
[5],α
3IA
[benzodiazepine
site](Inverse
agonist),D
M
C
M
[benzodiazepine
site](Inverse
agonist)
flum
azenil[benzodiazepine
site](Partialagonist)
(pK
i 6.8)
[159],bretazenil
[benzodiazepine
site](Fullagonist)
Selective
allosteric
m
odulators
α
5IA
[benzodiazepine
site](Inverse
agonist),L655708
[benzodiazepine
site](Inverse
agonist),L838417
[benzodiazepine
site](Partialagonist),M
RK016
[benzodiazepine
site]
(Inverse
agonist),RO
4938581
[benzodiazepine
site](Inverse
agonist),RY024
[benzodiazepine
site](Inverse
agonist)
Ro15-4513
[benzodiazepine
site](Fullagonist)
Searchable
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w
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(continued)
N
om
enclature
G
ABA
A
receptorα
5
subunit
G
ABA
A
receptorα
6
subunit
Labelled
ligands
[ 3H
]RY80
[benzodiazepine
site](Selective
Binding)
(pK
d
9.2)
[335]–
Rat,
[ 11C
]flum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 18F]fluoroethylflum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 35S]TBPS
[anion
channel](C
hannelblocker),[ 3H
]C
G
S8216
[benzodiazepine
site]
(Allosteric
m
odulator,M
ixed),[ 3H
]L655708
[benzodiazepine
site](Allosteric
m
odulator,
Inverse
agonist),[ 3H
]flunitrazepam
[benzodiazepine
site](Allosteric
m
odulator,Full
agonist),[ 3H
]gabazine
[G
ABA
site](Antagonist),[ 3H
]m
uscim
ol[G
ABA
site](Agonist)
[ 11C
]flum
azenil[benzodiazepine
site](Allosteric
m
odulator,Partialagonist),
[ 18F]fluoroethylflum
azenil[benzodiazepine
site](Allosteric
m
odulator,Antagonist),
[ 35S]TBPS
[anion
channel](C
hannelblocker),[ 3H
]C
G
S8216
[benzodiazepine
site]
(Allosteric
m
odulator,M
ixed),[ 3H
]Ro154513
[benzodiazepine
site](Allosteric
m
odulator,Fullagonist),[ 3H
]gabazine
[G
ABA
site](Antagonist),[ 3H
]m
uscim
ol[G
ABA
site](Agonist)
C
om
m
ents
Zn
2+
is
an
endogenous
allosteric
regulator
and
causes
potent
inhibition
ofreceptors
form
ed
from
binary
com
binations
ofα
and
β
subunits,incorporation
ofa
δ
orγ
subunit
causes
a
m
odest,or
pronounced,reduction
in
inhibitory
potency,respectively
[208]
diazepam
and
flunitrazepam
are
not
active
at
this
subunit.Zn
2+
is
an
endogenous
allosteric
regulator
and
causes
potent
inhibition
ofreceptors
form
ed
from
binary
com
binations
ofα
and
β
subunits,incorporation
ofa
δ
orγ
subunit
causes
a
m
odest,
or
pronounced,reduction
in
inhibitory
potency,respectively
[208].[ 3H
]Ro154513
selectively
labelsα
6-subunit-containing
receptors
in
the
presence
ofa
saturating
concentration
ofa
’classical’benzodiazepine
(e.g.diazepam
)
N
om
enclature
G
ABA
A
receptorβ1
subunit
G
ABA
A
receptorβ2
subunit
G
ABA
A
receptorβ3
subunit
H
G
N
C
,U
niProt
G
ABRB1,P18505
G
ABRB2,P47870
G
ABRB3,P28472
C
hannelblockers
TBPS,picrotoxin
TBPS,picrotoxin
TBPS,picrotoxin
Allosteric
m
odulators
–
–
etazolate
(Binding)
(pIC
50
5.5)
[404]
C
om
m
ents
Zn
2+
is
an
endogenous
allosteric
regulator
and
causes
potent
inhibition
ofreceptors
form
ed
from
binary
com
binations
ofα
and
β
subunits,incorporation
ofa
δ
or
γ
subunit
causes
a
m
odest,or
pronounced,reduction
in
inhibitory
potency,respectively
[208]
N
om
enclature
G
ABA
A
receptorγ1
subunit
G
ABA
A
receptorγ2
subunit
G
ABA
A
receptorγ3
subunit
H
G
N
C
,U
niProt
G
ABRG
1,Q
8N
1C
3
G
ABRG
2,P18507
G
ABRG
3,Q
99928
C
hannelblockers
TBPS,picrotoxin
TBPS,picrotoxin
TBPS,picrotoxin
C
om
m
ents
Zn
2+
is
an
endogenous
allosteric
regulator
and
causes
potent
inhibition
ofreceptors
form
ed
from
binary
com
binations
ofα
and
β
subunits,incorporation
ofa
δ
or
γ
subunit
causes
a
m
odest,or
pronounced,reduction
in
inhibitory
potency,respectively
[208]
Searchable
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N
om
enclature
G
ABA
A
receptor
δ
subunit
G
ABA
A
receptor
ϵ
subunit
G
ABA
A
receptor
θ
subunit
G
ABA
A
receptor
π
subunit
H
G
N
C
,U
niProt
G
ABRD
,O
14764
G
ABRE,P78334
G
ABRQ
,Q
9U
N
88
G
ABRP,O
00591
Selective
agonists
gaboxadol[G
ABA
site]
–
–
–
C
hannelblockers
TBPS,picrotoxin
TBPS,picrotoxin
TBPS,picrotoxin
TBPS,picrotoxin
C
om
m
ents
Zn
2+
is
an
endogenous
allosteric
regulator
and
causes
potent
inhibition
ofreceptors
form
ed
from
binary
com
binations
ofα
and
β
subunits,incorporation
ofa
δ
orγ
subunitcauses
a
m
odest,orpronounced,reduction
in
inhibitory
potency,respectively
–
–
–
N
om
enclature
G
ABA
A
receptor
ρ
1
subunit
G
ABA
A
receptor
ρ
2
subunit
G
ABA
A
receptor
ρ
3
subunit
H
G
N
C
,U
niProt
G
ABRR1,P24046
G
ABRR2,P28476
G
ABRR3,A8M
PY1
Agonists
isoguvacine
[G
ABA
site](Partialagonist),
m
uscim
ol[G
ABA
site](Partialagonist)
isoguvacine
[G
ABA
site](Partialagonist),m
uscim
ol
[G
ABA
site](Partialagonist)
isoguvacine
[G
ABA
site](Partialagonist),m
uscim
ol[G
ABA
site]
(Partialagonist)
Selective
agonists
(±
)-cis-2-C
AM
P
[G
ABA
site],5-M
e-IAA
[G
ABA
site]
(±
)-cis-2-C
AM
P
[G
ABA
site],5-M
e-IAA
[G
ABA
site]
(±
)-cis-2-C
AM
P
[G
ABA
site],5-M
e-IAA
[G
ABA
site]
Antagonists
gaboxadol[G
ABA
site],isonipecotic
acid
[G
ABA
site],piperidine-4-sulphonic
acid
[G
ABA
site]
gaboxadol[G
ABA
site],isonipecotic
acid
[G
ABA
site],
piperidine-4-sulphonic
acid
[G
ABA
site]
gaboxadol[G
ABA
site],isonipecotic
acid
[G
ABA
site],
piperidine-4-sulphonic
acid
[G
ABA
site]
Selective
antagonists
cis-3-AC
PBPA
[G
ABA
site],trans-3-AC
PBPA
[G
ABA
site],TPM
PA
[G
ABA
site],aza-TH
IP
[G
ABA
site]
cis-3-AC
PBPA
[G
ABA
site],trans-3-AC
PBPA
[G
ABA
site],
TPM
PA
[G
ABA
site],aza-TH
IP
[G
ABA
site]
cis-3-AC
PBPA
[G
ABA
site],trans-3-AC
PBPA
[G
ABA
site],TPM
PA
[G
ABA
site],aza-TH
IP
[G
ABA
site]
C
hannelblockers
TBPS,picrotoxin
TBPS,picrotoxin
TBPS,picrotoxin
C
om
m
ents
bicuculline
is
not
active
at
this
subunit
bicuculline
is
not
active
at
this
subunit
bicuculline
is
not
active
at
this
subunit
C
o
m
m
en
ts:
Th
e
poten
cy
an
d
efficacy
of
m
an
y
G
A
BA
agon
ists
vary
betw
een
G
A
BA
A
receptor
isoform
s
[117,
188,
209].
For
ex-
am
ple,gaboxadolis
a
partialagon
istatreceptors
w
ith
th
e
subun
it
com
position
α
4β3γ2,butelicits
curren
ts
in
excess
ofth
ose
evoked
by
G
A
BA
atth
e
α
4β3δ
receptor
w
h
ere
G
A
BA
itselfis
a
low
efficacy
agon
ist
[32,
43].
Th
e
an
tagon
ists
bicucullin
e
an
d
gabazin
e
differ
in
th
eirability
to
suppressspon
tan
eousopen
in
gsofth
e
G
A
BA
A
re-
ceptor,th
e
form
er
bein
g
m
ore
effective
[359].Th
e
presen
ce
ofth
e
γ
subun
it
w
ith
in
th
e
h
eterotrim
eric
com
plex
reduces
th
e
poten
cy
an
d
efficacy
of
agon
ists
[347].
Th
e
G
A
BA
A
receptor
con
tain
s
dis-
tin
ct
allosteric
sites
th
at
bin
d
barbiturates
an
d
en
dogen
ous
(e.g.,
5α
-pregn
an
-3α
-ol-20-on
e)
an
d
syn
th
etic
(e.g.,
alph
axalon
e)
n
eu-
roactive
steroids
in
a
diastereo-
or
en
an
tio-selective
m
an
n
er
[28,
143,
154,
368].
Picrotoxin
in
an
d
TBPS
act
at
an
allosteric
site
w
ith
in
th
e
ch
loride
ch
an
n
el
pore
to
n
egatively
regulate
ch
an
n
el
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activity;
n
egative
allosteric
regulation
by
γ-butyrolacton
e
deriva-
tivesalso
in
volvesth
e
picrotoxin
in
site,w
h
ereaspositive
allosteric
regulation
by
such
com
poun
ds
is
proposed
to
occur
at
a
distin
ct
locus.
M
an
y
in
traven
ous
(e.g.,
etom
idate,
propofol)
an
d
in
h
ala-
tion
al
(e.g.,
h
aloth
an
e,
isofluran
e)
an
aesth
etics
an
d
alcoh
ols
also
exert
a
regulatory
in
fluen
ce
upon
G
A
BA
A
receptor
activity
[38,
285].
Specific
am
in
o
acid
residues
w
ith
in
G
A
BA
A
receptor
α
-
an
d
β-subun
its
th
at
in
fluen
ce
allosteric
regulation
by
an
aesth
etic
an
d
n
on
-an
aesth
etic
com
poun
dsh
ave
been
iden
tified
[141,154].Ph
o-
toaffin
ity
labellin
g
ofdistin
ct
am
in
o
acid
residues
w
ith
in
purified
G
A
BA
A
receptors
by
th
e
etom
idate
derivative,
[ 3H
]azietom
idate,
h
as
also
been
dem
on
strated
[221]
an
d
th
is
bin
din
g
subject
to
positive
allosteric
regulation
by
an
aesth
etic
steroids
[220].
A
n
array
of
n
atural
products
in
cludin
g
flavon
oid
an
d
terpen
oid
com
poun
ds
exert
varied
action
s
at
G
A
BA
A
receptors
(review
ed
in
detailin
[181]).
In
addition
to
th
e
agen
ts
listed
in
th
e
table,m
odulators
ofG
A
BA
A
receptor
activity
th
at
exh
ibit
subun
it
depen
den
t
activity
in
clude:
salicyliden
e
salicylh
ydrazide
[n
egative
allosteric
m
odulator
selec-
tive
for
β1-
versus
β2-,or
β3-subun
it-con
tain
in
g
receptors
[360]];
fragren
t
dioxan
e
derivatives
[positive
allosteric
m
odulators
selec-
tive
for
β1-
versus
β2-,or
β3-subun
it-con
tain
in
g
receptors
[328]];
loreclezole,
etom
idate,
tracazolate,
m
efen
am
ic
acid,
etifoxin
e,
stiripen
tol,
valeren
ic
acid
am
ide
[positive
allosteric
m
odulators
w
ith
selectivity
for
β2/β3-
over
β1-subun
it-con
tain
in
g
receptors
[112,
198,
206]];
tracazolate
[in
trin
sic
efficacy,
i.e.,
poten
tiation
,
or
in
h
ibition
,
is
depen
den
t
upon
th
e
iden
tity
of
th
e
γ1-3-,
δ-,
or
ϵ-subun
itco-assem
bed
w
ith
α
1-an
d
β1-subun
its
[358]];am
iloride
[selective
blockade
of
receptors
con
tain
in
g
an
α
6-subun
it
[115]];
furosem
ide
[selective
blockade
of
receptors
con
tain
in
g
an
α
6-
subun
itco-assem
bled
w
ith
β2/β3-,butn
otβ1-subun
it[206]];La 3+
[poten
tiates
respon
ses
m
ediated
by
α
1β3γ2L
receptors,w
eakly
in
-
h
ibits
α
6β3γ2L
receptors,
an
d
stron
gly
blocks
α
6β3δ
an
d
α
4β3δ
receptors
[43,
321]];
eth
an
ol
[selectively
poten
tiates
respon
ses
m
ediated
by
α
4β3δ
an
d
α
6β3δ
receptors
versus
receptors
in
w
h
ich
β2
replaces
β3,
or
γ
replaces
δ
[378],
but
see
also
[205]];
D
S1
an
d
D
S2
[selectively
poten
tiate
respon
ses
m
ediated
by
δ-subun
it-
con
tain
in
g
receptors
[374]].
It
sh
ould
be
n
oted
th
at
th
e
appar-
en
t
selectivity
ofsom
e
positive
allosteric
m
odulators
(e.g.,n
euros-
teroids
such
as
5α
-pregn
an
-3α
-ol-20-on
e
for
δ-subun
it-con
tain
in
g
receptors
(e.g.,α
1β3δ)m
ay
be
a
con
sequen
ce
ofth
e
un
usually
low
efficacy
of
G
A
BA
at
th
is
receptor
isoform
[27,32].
Fu
rth
er
read
in
g
o
n
G
A
B
A
A
recep
to
rs
Braat,S
et
al.
(2015)
Th
e
G
A
BA
A
R
eceptor
as
a
Th
erapeutic
Target
for
N
eurodevelopm
en
tal
D
isor-
ders.N
euron
86
:1119-30
[PM
ID
:26050032]
C
alvo,D
Jetal.(2016)D
yn
am
ic
R
egulation
ofth
e
G
A
BA
A
R
eceptorFun
ction
by
R
edox
M
ech
an
ism
s.
M
olPharm
acol90
:326-33
[PM
ID
:27439531]
Locci,
A
et
al.
(2017)
N
eurosteroid
biosyn
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dow
n
regulation
an
d
ch
an
ges
in
G
A
BA
A
receptor
subun
it
com
position
:A
biom
arker
axis
in
stress-in
duced
cogn
itive
an
d
em
otion
alim
pairm
en
t.
Br
JPharm
acol[PM
ID
:28456011]
M
ele,
M
et
al.
(2016)
R
ole
of
G
A
BA
A
R
traffickin
g
in
th
e
plasticity
of
in
h
ibitory
syn
apses.
J
N
eu-
rochem
139
:997-1018
[PM
ID
:27424566]
O
lsen
,
RW
et
al.
(2008)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
LX
X
.
Subtypes
of
gam
m
a-
am
in
obutyric
acid(A
)
receptors:
classification
on
th
e
basis
of
subun
it
com
position
,
ph
arm
a-
cology,an
d
fun
ction
.U
pdate.
Pharm
acolRev
60
:243-60
[PM
ID
:18790874]
G
lycine
receptors
Ligan
d-gated
ion
ch
an
n
els→
G
lycin
e
receptors
O
verview
:
Th
e
in
h
ibitory
glycin
e
receptor
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
G
lycin
e
R
e-
cep
to
rs)is
a
m
em
ber
ofth
e
C
ys-loop
superfam
ily
oftran
sm
itter-
gated
ion
ch
an
n
els
th
at
in
cludes
th
e
zin
c
activated
ch
an
n
els,
G
A
BA
A
,
n
icotin
ic
acetylch
olin
e
an
d
5-H
T
3
receptors
[233].
Th
e
receptor
is
expressed
eith
er
as
a
h
om
o-pen
tam
er
ofα
subun
its,or
a
com
plex
n
ow
th
ough
t
to
h
arbour
2α
an
d
3β
subun
its
[30,129],
th
at
con
tain
an
in
trin
sic
an
ion
ch
an
n
el.
Four
differen
tially
ex-
pressed
isoform
s
of
th
e
α
-subun
it
(α
1-α
4)
an
d
on
e
varian
t
of
th
e
β-subun
it
(β1,
G
LRB,
P48167)
h
ave
been
iden
tified
by
gen
om
ic
an
d
cD
N
A
clon
in
g.
Furth
er
diversity
origin
ates
from
altern
ative
splicin
g
of
th
e
prim
ary
gen
e
tran
scripts
for
α
1
(α
1
IN
S
an
d
α
1
del),
α
2
(α
2A
an
d
α
2B),α
3
(α
3S
an
d
α
3L)
an
d
β
(β&
7)
subun
its
an
d
by
m
R
N
A
editin
g
of
th
e
α
2
an
d
α
3
subun
it
[103,249,284].
Both
α
2
splicin
g
an
d
α
3
m
R
N
A
editin
g
can
produce
subun
its
(i.e.,α
2B
an
d
α
3P185L)
w
ith
en
h
an
ced
agon
ist
sen
sitivity.
Predom
in
an
tly,
th
e
m
ature
form
of
th
e
receptor
con
tain
s
α
1
(or
α
3)
an
d
β
sub-
un
its
w
h
ile
th
e
im
m
ature
form
is
m
ostly
com
posed
of
on
ly
α
2
subun
its.R
N
A
tran
scripts
en
codin
g
th
e
α
4-subun
ith
ave
n
otbeen
detected
in
adult
h
um
an
s.
Th
e
N
-term
in
al
dom
ain
of
th
e
α
-
subun
it
con
tain
s
both
th
e
agon
ist
an
d
strych
n
in
e
bin
din
g
sites
th
at
con
sist
of
several
discon
tin
uous
region
s
of
am
in
o
acids.
In
-
clusion
of
th
e
β-subun
it
in
th
e
pen
tam
eric
glycin
e
receptor
con
-
tributes
to
agon
ist
bin
din
g,
reduces
sin
gle
ch
an
n
el
con
ductan
ce
an
d
alters
ph
arm
acology.
Th
e
β-subun
it
also
an
ch
ors
th
e
recep-
tor,
via
an
am
ph
ipath
ic
sequen
ce
w
ith
in
th
e
large
in
tracellular
loop
region
,
to
geph
yrin
.
Th
e
latter
is
a
cytoskeletal
attach
m
en
t
protein
th
at
bin
ds
to
a
n
um
ber
of
subsyn
aptic
protein
s
in
volved
in
cytoskeletal
structure
an
d
th
us
clusters
an
d
an
ch
ors
h
etero-
oligom
eric
receptors
to
th
e
syn
apse
[201,204,268].
G
-protein
βγ
subun
its
en
h
an
ce
th
e
open
state
probability
ofn
ative
an
d
recom
-
bin
an
t
glycin
e
receptors
by
association
w
ith
dom
ain
s
w
ith
in
th
e
large
in
tracellular
loop
[397,
398].
In
tracellular
ch
loride
con
cen
-
tration
m
odulates
th
e
kin
etics
of
n
ative
an
d
recom
bin
an
t
glycin
e
receptors
[304].
In
tracellular
C
a 2+
appears
to
in
crease
n
ative
an
d
recom
bin
an
t
glycin
e
receptor
affin
ity,
prolon
gin
g
ch
an
n
el
open
even
ts,
by
a
m
ech
an
ism
th
at
does
n
ot
in
volve
ph
osph
orylation
[118].
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
G
lycine
receptors
S142
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13879/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:Ligand-gated
ion
channels.British
JournalofPharm
acology
(2017)174,S130–S159
N
om
enclature
glycine
receptorα
1
subunit
glycine
receptorα
2
subunit
glycine
receptorα
3
subunit
glycine
receptorα
4
subunit
(pseudogene
in
hum
ans)
H
G
N
C
,U
niProt
G
LRA1,P23415
G
LRA2,P23416
G
LRA3,O
75311
G
LRA4,Q
5JX
X
5
Selective
agonists
(potency
order)
glycine
>
β-alanine
>
taurine
glycine
>
β-alanine
>
taurine
glycine
>
β-alanine
>
taurine
–
Selective
antagonists
ginkgolide
X
(pIC
50
6.1),pregnenolone
sulphate
(pK
i 5.7),nifedipine
(pIC
50
5.5),bilobalide
(pIC
50
4.7),tropisetron
(pK
i 4.1),colchicine
(pIC
50
3.5),
H
U
-308
(w
eak
inhibition),PM
BA,strychnine
H
U
-210
(pIC
50
7),W
IN
55212-2
(pIC
50
6.7),H
U
-308
(pIC
50
6),ginkgolide
X
(pIC
50
5.6),
pregnenolone
sulphate
(pK
i 5.3),bilobalide
(pIC
50
5.1),tropisetron
(pK
i 4.9),colchicine
(pIC
50
4.2),
5,7-dichlorokynurenic
acid
(pIC
50
3.7),PM
BA,
strychnine
H
U
-210
(pIC
50
7.3),H
U
-308
(pIC
50
7),W
IN
55212-2
(pIC
50
7),
(12E,20Z,18S)-8-hydroxyvariabilin
(pIC
50
5.2),nifedipine
(pIC
50
4.5),
strychnine
–
C
hannelblockers
ginkgolide
B
(pIC
50
5.1–6.2),cyanotriphenylborate
(pIC
50
5.9)
[316],picrotin
(pIC
50
5.3),picrotoxinin
(pIC
50
5.3),picrotoxin
(pIC
50
5.2)
picrotoxinin
(pIC
50
6.4),picrotoxin
(pIC
50
5.6),
ginkgolide
B
(pIC
50
4.9–5.4),picrotin
(pIC
50
4.9),
cyanotriphenylborate
(pIC
50
>
4.7)
[316]
picrotoxinin
(pIC
50
6.4),ginkgolide
B
(pIC
50
5.7),picrotin
(pIC
50
5.2),
picrotoxin
(block
is
w
eaker
w
hen
β
subunit
is
co-expressed)
–
Endogenous
allosteric
m
odulators
Zn
2+
(Potentiation)
(pEC
50
7.4),C
u
2+
(Inhibition)
(pIC
50
4.8–5.4),Zn
2+
(Inhibition)
(pIC
50
4.8),
Extracellular
H
+
(Inhibition)
Zn
2+
(Potentiation)
(pEC
50
6.3),C
u
2+
(Inhibition)
(pIC
50
4.8),Zn
2+
(Inhibition)
(pIC
50
3.4)
C
u
2+
(Inhibition)
(pIC
50
5),Zn
2+
(Inhibition)
(pIC
50
3.8)
–
Selective
allosteric
m
odulators
anandam
ide
(Potentiation)
(pEC
50
7.4),H
U
-210
(Potentiation)
(pEC
50
6.6),
&
9-tetrahydrocannabinol(Potentiation)
(pEC
50
∼
5.5)
&
9-tetrahydrocannabinol(Potentiation)
(pEC
50 ∼
6)
&
9-tetrahydrocannabinol
(Potentiation)
(pEC
50 ∼
5.3)
–
Labelled
ligands
[ 3H
]strychnine
(Antagonist)
[ 3H
]strychnine
(Antagonist)
[ 3H
]strychnine
(Antagonist)
–
FunctionalC
haracteristics
γ
=
86
pS
(m
ain
state);(+
β
=
44
pS)
γ
=
111
pS
(m
ain
state);(+
β
=
54
pS)
γ
=
105
pS
(m
ain
state);(+
β
=
48)
–
N
om
enclature
glycine
receptorβ
subunit
H
G
N
C
,U
niProt
G
LRB,P48167
Selective
antagonists
nifedipine
(w
hen
co-expressed
w
ith
the
α
1
subunit)
(pIC
50
5.9),pregnenolone
sulphate
(w
hen
co-expressed
w
ith
the
α
1
subunit)
(pK
i 5.6),tropisetron
(w
hen
co-expressed
w
ith
the
α
2
subunit)
(pK
i 5.3),pregnenolone
sulphate
(w
hen
co-expressed
w
ith
the
α
2
subunit)
(pK
i 5),nifedipine
(w
hen
co-expressed
w
ith
the
α
3
subunit)
(pIC
50
4.9),bilobalide
(w
hen
co-expressed
w
ith
the
α
2
subunit)
(pIC
50
4.3),bilobalide
(w
hen
co-expressed
w
ith
the
α
1
subunit)
(pIC
50
3.7),ginkgolide
X
(w
hen
co-expressed
w
ith
the
α
1
subunit)
(pIC
50
>
3.5),ginkgolide
X
(w
hen
co-expressed
w
ith
the
α
2
subunit)
(pIC
50
>
3.5)
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(continued)
N
om
enclature
glycine
receptorβ
subunit
C
hannelblockers
ginkgolide
B
(w
hen
co-expressed
w
ith
the
α
2
subunit)
(pIC
50
6.1–6.9),ginkgolide
B
(w
hen
co-expressed
w
ith
the
α
1
subunit)
(pIC
50
5.6–6.7),ginkgolide
B
(w
hen
co-expressed
w
ith
the
α
3
subunit)
(pIC
50
6.3),cyanotriphenylborate
(w
hen
co-expressed
w
ith
the
hum
an
α
1
subunit)
(pIC
50
5.6)
[316]–
Rat,cyanotriphenylborate
(w
hen
co-expressed
w
ith
the
hum
an
α
2
subunit)
(pIC
50
5.1)
[316]–
Rat,picrotoxinin
(w
hen
co-expressed
w
ith
the
α
3
subunit)
(pIC
50
5.1),picrotin
(w
hen
co-expressed
w
ith
the
α
1
subunit)
(pIC
50
4.6),
picrotin
(w
hen
co-expressed
w
ith
the
α
3
subunit)
(pIC
50
4.6),picrotoxinin
(w
hen
co-expressed
w
ith
the
α
1
subunit)
(pIC
50
4.6),picrotoxin
(w
hen
co-expressed
w
ith
the
α
2
subunit)
(pIC
50
4.5),picrotoxin
(w
hen
co-expressed
w
ith
the
α
1
subunit)
(pIC
50
3.7)
Endogenous
allosteric
m
odulators
Zn
2+
(Inhibition)
(pIC
50
4.9),Zn
2+
(Inhibition)
(pIC
50
3.7)
C
om
m
ents
Ligand
interaction
data
for
hetero-oligom
er
receptors
containing
the
β
subunit
are
also
listed
under
the
α
subunit
C
o
m
m
en
ts:
D
ata
in
th
e
table
refer
to
h
om
o-oligom
eric
assem
-
blies
of
th
e
α
-subun
it,
sign
ifican
t
ch
an
ges
in
troduced
by
co-
expression
of
th
e
β1
subun
it
are
in
dicated
in
paren
th
esis.
N
ot
all
glycin
e
receptor
ligan
ds
are
listed
w
ith
in
th
e
table,but
som
e
th
at
m
ay
be
usefulin
distin
guish
in
g
betw
een
glycin
e
receptorisoform
s
are
in
dicated
(see
detailed
view
pages
for
each
subun
it:
α
1,
α
2,
α
3,
α
4,
β
).
Pregn
en
olon
e
sulph
ate,
tropisetron
an
d
colch
icin
e,
for
exam
ple,alth
ough
n
ot
selective
an
tagon
ists
of
glycin
e
recep-
tors,
are
in
cluded
for
th
is
purpose.
Strych
n
in
e
is
a
poten
t
an
d
selective
com
petitive
glycin
e
receptor
an
tagon
istw
ith
affin
ities
in
th
e
ran
ge
5–15
n
M
.
R
U
5135
dem
on
strates
com
parable
poten
cy,
butaddition
ally
blocks
G
A
BA
A
receptors.Th
ere
are
con
flictin
g
re-
ports
con
cern
in
g
th
e
ability
of
can
n
abin
oids
to
in
h
ibit
[228],
or
poten
tiate
an
d
at
h
igh
con
cen
tration
s
activate
[3,
83,
140,
389,
394]
glycin
e
receptors.
N
on
eth
eless,can
n
abin
oid
an
alogues
m
ay
h
old
prom
ise
in
distin
guish
in
g
betw
een
glycin
e
receptor
subtypes
[394].
In
addition
,
poten
tiation
of
glycin
e
receptor
activity
by
can
n
abin
oids
h
as
been
claim
ed
to
con
tribute
to
can
n
abis-in
duced
an
algesia
relyin
g
on
Ser296/307
(α
1/α
3)in
M
3
[389].Severalan
a-
logues
of
m
uscim
ol
an
d
piperidin
e
act
as
agon
ists
an
d
an
tago-
n
ists
of
both
glycin
e
an
d
G
A
BA
A
receptors.
Picrotoxin
acts
as
an
allosteric
in
h
ibitor
th
at
appears
to
bin
d
w
ith
in
th
e
pore,
an
d
sh
ow
s
stron
g
selectivity
tow
ards
h
om
om
eric
receptors.
W
h
ile
its
com
pon
en
ts,
picrotoxin
in
an
d
picrotin
,
h
ave
equal
poten
cies
at
α
1
receptors,
th
eir
poten
cies
at
α
2
an
d
α
3
receptors
differ
m
od-
estly
an
d
m
ay
allow
som
e
distin
ction
betw
een
differen
t
recep-
tor
types
[395].
Bin
din
g
of
picrotoxin
w
ith
in
th
e
pore
h
as
been
dem
on
strated
in
th
e
crystal
structure
of
th
e
related
C
.
elegans
G
luC
l
C
ys-loop
receptor
[144].
In
addition
to
th
e
com
poun
ds
listed
in
th
e
table,n
um
erous
agen
ts
act
as
allosteric
regulators
of
glycin
e
receptors
(com
preh
en
sively
review
ed
in
[215,
234,
381,
399]).
Zn
2+
acts
th
rough
distin
ct
bin
din
g
sites
of
h
igh
-
an
d
low
-
affin
ity
to
allosterically
en
h
an
ce
ch
an
n
el
fun
ction
at
low
(<
10
µ
M
)
con
cen
tration
s
an
d
in
h
ibits
respon
ses
at
h
igh
er
con
cen
tra-
tion
s
in
a
subun
it
selective
m
an
n
er
[258].
Th
e
effect
of
Zn
2+
is
som
ew
h
at
m
im
icked
by
N
i 2+.
En
dogen
ous
Zn
2+
is
essen
tial
for
n
orm
al
glycin
ergic
n
eurotran
sm
ission
m
ediated
by
α
1
subun
it-
con
tain
in
g
receptors
[147].
Elevation
of
in
tracellular
C
a 2+
pro-
duces
fast
poten
tiation
of
glycin
e
receptor-m
ediated
respon
ses.
D
ideoxyforskolin
(4
µ
M
)
an
d
tam
oxifen
(0.2–5
µ
M
)
both
poten
-
tiate
respon
ses
to
low
glycin
e
con
cen
tration
s
(15
µ
M
),
but
act
as
in
h
ibitors
at
h
igh
er
glycin
e
con
cen
tration
s
(100
µ
M
).
A
ddi-
tion
alm
odulatory
agen
ts
th
at
en
h
an
ce
glycin
e
receptor
fun
ction
in
clude
in
h
alation
al,
an
d
several
in
traven
ous
gen
eral
an
aesth
et-
ics
(e.g.
m
in
axolon
e,
propofol
an
d
pen
tobarbiton
e)
an
d
certain
n
eurosteroids.
Eth
an
olan
d
h
igh
er
order
n
-alcoh
ols
also
en
h
an
ce
glycin
e
receptor
fun
ction
alth
ough
w
h
eth
er
th
is
occurs
by
a
di-
rect
allosteric
action
at
th
e
receptor
[245],or
th
rough
βγ
subun
its
[396]
is
debated.
R
ecen
t
crystal
structures
of
th
e
bacterial
h
om
o-
logue,G
LIC
,h
ave
iden
tified
tran
sm
em
bran
e
bin
din
g
pockets
for
both
an
aesth
etics
[282]
an
d
alcoh
ols
[156].
Solven
ts
in
h
aled
as
drugsofabuse
(e.g.toluen
e,1-1-1-trich
loroeth
an
e)m
ay
actatsites
th
at
overlap
w
ith
th
ose
recogn
isin
g
alcoh
ols
an
d
volatile
an
aes-
th
etics
to
produce
poten
tiation
of
glycin
e
receptor
fun
ction
.
Th
e
fun
ction
of
glycin
e
receptors
form
ed
as
h
om
om
eric
com
plexes
of
α
1
or
α
2
subun
its,
or
h
etero-oligom
ers
of
α
1/β
or
α
2/β
sub-
un
its,
is
differen
tially
affected
by
th
e
5-H
T
3
receptor
an
tagon
ist
tropisetron
(IC
S
205-930)
w
h
ich
m
ay
evoke
poten
tiation
(w
h
ich
m
ay
occurw
ith
in
th
e
fem
tom
olarran
ge
atth
e
h
om
om
eric
glycin
e
α
1
receptor),or
in
h
ibition
,depen
din
g
upon
th
e
subun
it
com
po-
sition
of
th
e
receptor
an
d
th
e
con
cen
tration
s
of
th
e
m
odulator
an
d
glycin
e
em
ployed.
Poten
tiation
an
d
in
h
ibition
by
tropein
es
in
volves
differen
t
bin
din
g
m
odes
[238].
A
ddition
altropein
es,in
-
cludin
g
atropin
e,m
odulate
glycin
e
receptor
activity.
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Ionotropic
glutam
ate
receptors
Ligan
d-gated
ion
ch
an
n
els→
Ion
otropic
glutam
ate
receptors
O
verview
:
Th
e
ion
otropic
glutam
ate
receptors
com
prise
m
em
-
bers
of
th
e
N
M
D
A
(N
-m
eth
yl-D
-aspartate),
A
M
PA
(α
-am
in
o-
3-h
ydroxy-5-m
eth
yl-4-isoxazoleproprion
ic
acid)
an
d
kain
ate
receptor
classes,
n
am
ed
origin
ally
accordin
g
to
th
eir
preferred,
syn
th
etic,
agon
ist
[86,
226,
365].
R
eceptor
h
eterogen
eity
w
ith
in
each
class
arises
from
th
e
h
om
o-oligom
eric,or
h
etero-oligom
eric,
assem
bly
of
distin
ct
subun
its
in
to
cation
-selective
tetram
ers.
Each
subun
it
of
th
e
tetram
eric
com
plex
com
prises
an
extra-
cellular
am
in
o
term
in
al
dom
ain
(A
TD
),
an
extracellular
ligan
d
bin
din
g
dom
ain
(LBD
),th
ree
tran
sm
em
bran
e
dom
ain
s
com
posed
of
th
ree
m
em
bran
e
span
s
(M
1,
M
3
an
d
M
4),
a
ch
an
n
el
lin
in
g
re-en
tran
t
‘p-loop’
(M
2)
located
betw
een
M
1
an
d
M
3
an
d
an
in
-
tracellular
carboxy-
term
in
al
dom
ain
(C
TD
)
[184,
211,
246,
271,
365].
Th
e
X
-ray
structure
of
a
h
om
om
eric
ion
otropic
glutam
ate
receptor
(G
luA
2
–
see
below
)
h
as
recen
tly
been
solved
at
3.6Å
resolution
[340]an
d
alth
ough
providin
g
th
e
m
ostcom
plete
struc-
turalin
form
ation
curren
t
available
m
ay
n
ot
represen
tative
of
th
e
subun
it
arran
gem
en
t
of,for
exam
ple,th
e
h
eterom
eric
N
M
D
A
re-
ceptors
[187].It
is
beyon
d
th
e
scope
ofth
is
supplem
en
t
to
discuss
th
e
ph
arm
acology
of
in
dividual
ion
otropic
glutam
ate
receptor
isoform
s
in
detail;
such
in
form
ation
can
be
glean
ed
from
[62,
74,86,106,171,177,195,288,289,290,365,388].
A
gen
ts
th
at
discrim
in
ate
betw
een
subun
it
isoform
s
are,
w
h
ere
appropriate,
n
oted
in
th
e
tables
an
d
addition
al
com
poun
ds
th
at
distin
guish
betw
een
receptor
isoform
s
are
in
dicated
in
th
e
text
below
.
T
h
e
classifi
catio
n
o
f
g
lu
tam
ate
recep
to
r
su
b
u
n
its
h
as
b
een
re-ad
d
ressed
b
y
N
C
-IU
P
H
A
R
[71].Th
e
sch
em
e
developed
recom
m
en
ds
a
n
om
en
clature
for
ion
otropic
glutam
ate
receptor
subun
its
th
at
is
adopted
h
ere.
A
M
PA
an
d
K
ain
ate
recep
to
rs
A
M
PA
receptors
assem
ble
as
h
om
om
ers,
or
h
eterom
ers,
th
at
m
ay
be
draw
n
from
G
luA
1,
G
luA
2,
G
luA
3
an
d
G
luA
4
an
d
G
luD
1,
G
luD
2,
G
luK
1,
G
luK
2,
G
luK
3,
G
luK
4
an
d
G
luK
5
sub-
un
its.Tran
sm
em
bran
e
A
M
PA
receptorregulatory
protein
s(TA
R
Ps)
of
class
I
(i.e.
γ2,
γ3,
γ4
an
d
γ8)
act,
w
ith
variable
stoich
iom
e-
try,
as
auxiliary
subun
its
to
A
M
PA
receptors
an
d
in
fluen
ce
th
eir
traffickin
g,sin
gle
ch
an
n
elcon
ductan
ce
gatin
g
an
d
ph
arm
acology
(review
ed
in
[108,
165,
260,
362]).
Fun
ction
al
kain
ate
receptors
can
be
expressed
as
h
om
om
ers
of
G
luK
1,
G
luK
2
or
G
luK
3
sub-
un
its.
G
luK
1-3
subun
its
are
also
capable
of
assem
blin
g
in
to
h
et-
erotetram
ers
(e.g.
G
luK
1/K
2;
[218,
300,
303]).
Tw
o
addition
al
kain
ate
receptor
subun
its,G
luK
4
an
d
G
luK
5,w
h
en
expressed
in
-
dividually,
form
h
igh
affin
ity
bin
din
g
sites
for
kain
ate,
but
lack
fun
ction
,but
can
form
h
eterom
ers
w
h
en
expressed
w
ith
G
luK
1-3
subun
its
(e.g.
G
luK
2/K
5;
review
ed
in
[171,
300,
303]).
K
ain
ate
receptors
m
ay
also
exh
ibit
‘m
etabotropic’
fun
ction
s
[218,
312].
A
s
foun
d
for
A
M
PA
receptors,kain
ate
receptors
are
m
odulated
by
auxiliary
subun
its
(N
eto
protein
s,[219,300]).A
n
im
portan
tfun
c-
tion
differen
ce
betw
een
A
M
PA
an
d
kain
ate
receptorsisth
atth
e
lat-
ter
require
extracellular
N
a+
an
d
C
l-for
th
eir
activation
[40,306].
R
N
A
en
codin
g
th
e
G
luA
2
subun
it
un
dergoes
exten
sive
R
N
A
edit-
in
g
in
w
h
ich
th
e
codon
en
codin
g
a
p-loop
glutam
in
e
residue
(Q
)is
con
verted
to
on
e
en
codin
g
argin
in
e
(R
).Th
is
Q
/R
site
stron
gly
in
-
fluen
ces
th
e
bioph
ysical
properties
of
th
e
receptor.
R
ecom
bin
an
t
A
M
PA
receptors
lackin
g
R
N
A
edited
G
luA
2
subun
its
are:
(1)
per-
m
eable
to
C
a 2+;(2)
blocked
by
in
tracellular
polyam
in
es
at
depo-
larized
poten
tials
causin
g
in
w
ard
rectification
(th
e
latter
bein
g
re-
duced
by
TA
R
Ps);(3)
blocked
by
extracellular
argiotoxin
an
d
Joro
spider
toxin
s
an
d
(4)
dem
on
strate
h
igh
er
ch
an
n
el
con
ductan
ces
th
an
receptors
con
tain
in
g
th
e
edited
form
of
G
luA
2
[163,
326].
G
luK
1
an
d
G
luK
2,
but
n
ot
oth
er
kain
ate
receptor
subun
its,
are
sim
ilarly
edited
an
d
broadly
sim
ilar
fun
ction
alch
aracteristics
ap-
ply
to
kain
ate
receptors
lackin
g
eith
er
an
R
N
A
edited
G
luK
1,
or
G
luK
2,
subun
it
[218,
300].
N
ative
A
M
PA
an
d
kain
ate
receptors
displayin
g
differen
tialch
an
n
elcon
ductan
ces,C
a 2+
perm
eabilites
an
d
sen
sitivity
to
block
by
in
tracellular
polyam
in
es
h
ave
been
iden
tified
[73,163,224].G
luA
1-4
can
exist
as
tw
o
varian
ts
gen
er-
ated
by
altern
ative
splicin
g
(term
ed
‘flip’an
d
‘flop’)
th
at
differ
in
th
eir
desen
sitization
kin
etics
an
d
th
eir
desen
sitization
in
th
e
pres-
en
ce
of
cycloth
iazide
w
h
ich
stabilises
th
e
n
on
desen
sitized
state.
TA
R
Ps
also
stabilise
th
e
n
on
-desen
sitized
con
form
ation
of
A
M
PA
receptors
an
d
facilitate
th
e
action
of
cycloth
iazide
[260].
Splice
varian
ts
of
G
luK
1-3
also
exist
w
h
ich
affects
th
eir
traffickin
g
[218,
300].
N
om
enclature
G
luA1
G
luA2
G
luA3
G
luA4
H
G
N
C
,U
niProt
G
RIA1,P42261
G
RIA2,P42262
G
RIA3,P42263
G
RIA4,P48058
Agonists
(S)-5-fluorow
illardiine,AM
PA
(S)-5-fluorow
illardiine,AM
PA
(S)-5-fluorow
illardiine,AM
PA
(S)-5-fluorow
illardiine,AM
PA
Selective
antagonists
ATPO
,G
YKI53655,G
YKI53784
(active
isom
er,non-com
petitive),N
BQ
X
,
tezam
panel
ATPO
,G
YKI53655,G
YKI53784
(active
isom
er,non-com
petitive),N
BQ
X
,
tezam
panel
ATPO
,G
YKI53655,G
YKI53784
(active
isom
er,non-com
petitive),N
BQ
X
,
tezam
panel
ATPO
,G
YKI53655,G
YKI53784
(active
isom
er,non-com
petitive),N
BQ
X
,
tezam
panel
C
hannelblockers
extracellular
argiotoxin,extracellular
joro
toxin
(selective
for
channels
lacking
G
luA2)
extracellular
argiotoxin
extracellular
argiotoxin,extracellular
joro
toxin
(selective
for
channels
lacking
G
luA2)
extracellular
argiotoxin,extracellular
joro
toxin
(selective
for
channels
lacking
G
luA2)
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N
om
enclature
G
luA1
G
luA2
G
luA3
G
luA4
Allosteric
m
odulators
LY392098
(Positive)
(pEC
50
5.8)
[261],
LY404187
(Positive)
(pEC
50
5.2)
[261],
cyclothiazide
(Positive)
(pEC
50
4.7)
[261],
C
X
516
(Positive),C
X
546
(Positive),
ID
RA-21
(Positive),LY503430
(Positive),
S18986
(Positive),aniracetam
(Positive),
piracetam
(Positive)
LY404187
(Positive)
(pEC
50
6.8)
[261],
LY392098
(Positive)
(pEC
50
6.7)
[261],
cyclothiazide
(Positive)
(pEC
50
5.7)
[261],
C
X
516
(Positive),C
X
546
(Positive),ID
RA-21
(Positive),LY503430
(Positive),S18986
(Positive),aniracetam
(Positive),piracetam
(Positive)
LY404187
(Positive)
(pEC
50
5.8)
[261],
LY392098
(Positive)
(pEC
50
5.7)
[261],
cyclothiazide
(Positive)
(pEC
50
4.9)
[261],
C
X
516
(Positive),C
X
546
(Positive),ID
RA-21
(Positive),LY503430
(Positive),S18986
(Positive),aniracetam
(Positive),piracetam
(Positive)
LY392098
(Positive)
(pEC
50
6.7)
[261],
LY404187
(Positive)
(pEC
50
6.7)
[261],
cyclothiazide
(Positive)
(pEC
50
5.4)
[261],
C
X
516
(Positive),C
X
546
(Positive),
ID
RA-21
(Positive),LY503430
(Positive),
S18986
(Positive),aniracetam
(Positive),
piracetam
(Positive)
Labelled
ligands
[ 3H
]AM
PA
(Agonist),[ 3H
]C
N
Q
X
(Antagonist)
[ 3H
]AM
PA
(Agonist),[ 3H
]C
N
Q
X
(Antagonist)
[ 3H
]AM
PA,[ 3H
]C
N
Q
X
[ 3H
]AM
PA
(Agonist),[ 3H
]C
N
Q
X
C
om
m
ents
Also
blocked
by
intracellular
polyam
ines.
Also
blocked
by
intracellular
polyam
ines.
Also
blocked
by
intracellular
polyam
ines
Also
blocked
by
intracellular
polyam
ines
N
om
enclature
G
luD
1
G
luD
2
H
G
N
C
,U
niProt
G
RID
1,Q
9U
LK0
G
RID
2,O
43424
N
om
enclature
G
luK1
G
luK2
G
luK3
G
luK4
G
luK5
H
G
N
C
,U
niProt
G
RIK1,P39086
G
RIK2,Q
13002
G
RIK3,Q
13003
G
RIK4,Q
16099
G
RIK5,Q
16478
Endogenous
agonists
–
–
–
Agonists
dysiherbaine
[320]–
Rat,SYM
2081
[296],kainate
[336],(S)-4-AH
C
P,
(S)-5-iodow
illardiine,
8-deoxy-neodysiherbaine,ATPA,
dom
oic
acid
dysiherbaine
[320]–
Rat,
dom
oic
acid
[50],
SYM
2081
[413]–
Rat,
kainate
[50,336]
SYM
2081
[318]–
Rat,
kainate
(low
potency)
[318]–
Rat,dysiherbaine
SYM
2081,dom
oic
acid,dysiherbaine,
kainate
SYM
2081,dom
oic
acid,
dysiherbaine,kainate
Selective
agonists
LY339434
[342]
–
Selective
antagonists
2,4-epi-neodysiherbaine,AC
ET,
LY382884,LY466195,M
SVIII-19,
N
S3763
(non-com
petitive),U
BP302,
U
BP310
2,4-epi-neo
dysiherbaine
–
–
–
Allosteric
m
odulators
concanavalin
A
(Positive)
concanavalin
A
(Positive)
–
–
–
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N
om
enclature
G
luK1
G
luK2
G
luK3
G
luK4
G
luK5
Labelled
ligands
[ 3H
]U
BP310
(Antagonist)
(pK
d
7.7)
[13],[ 3H
]SYM
2081
(Agonist),
[ 3H
]kainate
(Agonist)
[ 3H
]kainate
(Agonist)
[407]–
Rat,
[ 3H
]SYM
2081
(Agonist)
[ 3H
]U
BP310
(Antagonist)
(pK
d
6.3)
[13],
[ 3H
]SYM
2081
(Agonist),
[ 3H
]kainate
(Agonist)
[ 3H
]SYM
2081
(Agonist),[ 3H
]kainate
(Agonist)
[ 3H
]SYM
2081
(Agonist),
[ 3H
]kainate
(Agonist)
C
om
m
ents
–
Intracellular
polyam
ines
are
subtype
selective
channelblockers
(G
luK3
≫
G
luK2)
dom
oic
acid
and
concanavalin
A
are
inactive
at
the
G
luK3
subunit.Intracellular
polyam
ines
are
subtype
selective
channelblockers
(G
luK3≫
G
luK2)
–
–
N
M
D
A
recep
to
rs
N
M
D
A
receptors
assem
ble
as
obligate
h
eterom
ers
th
at
m
ay
be
draw
n
from
G
luN
1,G
luN
2,G
luN
3
an
d
G
luN
4
subun
its.
A
ltern
a-
tive
splicin
g
can
gen
erate
eigh
t
isoform
s
of
G
luN
1
w
ith
differin
g
ph
arm
acological
properties.
V
arious
splice
varian
ts
of
G
luN
2B,
2C
,
2D
an
d
G
luN
3A
h
ave
also
been
reported.
A
ctivation
of
N
M
D
A
receptors
con
tain
in
g
G
luN
1
an
d
G
luN
2
subun
its
requires
th
e
bin
din
g
oftw
o
agon
ists,glutam
ate
to
th
e
S1
an
d
S2
region
s
of
th
e
G
luN
2
subun
it
an
d
glycin
e
to
S1
an
d
S2
region
s
ofth
e
G
luN
1
subun
it
[63,
105].
Th
e
m
in
im
al
requirem
en
t
for
efficien
t
fun
c-
tion
al
expression
of
N
M
D
A
receptors
in
vitro
is
a
di-h
eterom
eric
assem
bly
of
G
luN
1
an
d
at
least
on
e
G
luN
2
subun
it
varian
t,
as
a
dim
er
of
h
eterodim
ers
arran
gem
en
t
in
th
e
extracellular
dom
ain
[119,
187,
246].
H
ow
ever,
m
ore
com
plex
tri-h
eterom
eric
assem
-
blies,in
corporatin
g
m
ultiple
subtypesofG
luN
2
subun
it,orG
luN
3
subun
its,can
be
gen
eratedin
vitro
an
d
occurin
vivo.Th
e
N
M
D
A
re-
ceptorch
an
n
elcom
m
on
ly
h
asa
h
igh
relative
perm
eability
to
C
a 2+
an
d
isblocked,in
a
voltage-depen
den
tm
an
n
er,by
M
g
2+
such
th
at
at
restin
g
poten
tials
th
e
respon
se
is
substan
tially
in
h
ibited.
N
om
enclature
G
luN
1
G
luN
2A
G
luN
2B
G
luN
2C
G
luN
2D
H
G
N
C
,U
niProt
G
RIN
1,Q
05586
G
RIN
2A,Q
12879
G
RIN
2B,Q
13224
G
RIN
2C,Q
14957
G
RIN
2D
,O
15399
Endogenous
agonists
D
-aspartic
acid
[glutam
ate
site],
D
-serine
[glycine
site],
L-aspartic
acid
[glutam
ate
site],
glycine
[glycine
site]
D
-aspartic
acid
[glutam
ate
site](G
luN
2D
>
G
luN
2C
=
G
luN
2B
>
G
luN
2A),D
-serine
[glycine
site](G
luN
2D
>
G
luN
2C
>
G
luN
2B
>
G
luN
2A),L-aspartic
acid
[glutam
ate
site](G
luN
2D
=
G
luN
2B
>
G
luN
2C
=
G
luN
2A),glycine
[glycine
site](G
luN
2D
>
G
luN
2C
>
G
luN
2B
>
G
luN
2A)
D
-aspartic
acid
[glutam
ate
site](G
luN
2D
>
G
luN
2C
=
G
luN
2B
>
G
luN
2A),D
-serine
[glycine
site](G
luN
2D
>
G
luN
2C
>
G
luN
2B
>
G
luN
2A),L-aspartic
acid
[glutam
ate
site](G
luN
2D
=
G
luN
2B
>
G
luN
2C
=
G
luN
2A),glycine
[glycine
site](G
luN
2D
>
G
luN
2C
>
G
luN
2B
>
G
luN
2A)
Agonists
(+)-H
A966
[glycine
site](Partial
agonist),(RS)-(tetrazol-5-yl)glycine
[glutam
ate
site],N
M
D
A
[glutam
ate
site],
hom
oquinolinic
acid
[glutam
ate
site](Partialagonist)
(+)-H
A966
[glycine
site](Partialagonist),(RS)-(tetrazol-5-yl)glycine
[glutam
ate
site](G
luN
2D
>
G
luN
2C
=
G
luN
2B
>
G
luN
2A),N
M
D
A
[glutam
ate
site](G
luN
2D
>
G
luN
2C
>
G
luN
2B
>
G
luN
2A),
hom
oquinolinic
acid
[glutam
ate
site](G
luN
2B≥
G
luN
2A≥
G
luN
2D
>
G
luN
2C
;partialagonist
at
G
luN
2A
and
G
luN
2C
)
(RS)-(tetrazol-5-yl)glycine
[glutam
ate
site](G
luN
2D
>
G
luN
2C
=
G
luN
2B
>
G
luN
2A),N
M
D
A
[glutam
ate
site](G
luN
2D
>
G
luN
2C
>
G
luN
2B
>
G
luN
2A),hom
oquinolinic
acid
[glutam
ate
site](G
luN
2B
≥
G
luN
2A≥
G
luN
2D
>
G
luN
2C
;partialagonist
at
G
luN
2A
and
G
luN
2C
)
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N
om
enclature
G
luN
1
G
luN
2A
G
luN
2B
G
luN
2C
G
luN
2D
Selective
antagonists
L701324
[glycine
site](pIC
50
8.7)
[210]–
Rat,G
V196771A
[glycine
site](pK
i 8.1–8.4)
[67]–
Rat,
L689560
[glycine
site](pIC
50
8.1)
[217]–
Rat,
5,7-dichlorokynurenic
acid
[glycine
site]
5,7-dichlorokynurenic
acid
[glycine
site],C
G
P37849
[glutam
ate
site],
G
V196771A
[glycine
site],L689560
[glycine
site],L701324
[glycine
site],LY233053
[glutam
ate
site],N
VP-AAM
077
[glutam
ate
site]
(G
luN
2A
>
G
luN
2B
(hum
an),but
w
eakly
selective
for
rat
G
luN
2A
versus
G
luN
2B)
[14,110,116,273],U
BP141
[glutam
ate
site]
(G
luN
2D
≥
G
luN
2C
>
G
luN
2A≥
G
luN
2B)
[266],conantokin-G
[glutam
ate
site](G
luN
2B
>
G
luN
2D
=
G
luN
2C
=
G
luN
2A),d-AP5
[glutam
ate
site],d-C
C
Pene
[glutam
ate
site](G
luN
2A
=
G
luN
2B
>
G
luN
2C
=
G
luN
2D
),selfotel[glutam
ate
site]
5,7-dichlorokynurenic
acid
[glycine
site],C
G
P37849
[glutam
ate
site],
G
V196771A
[glycine
site],L689560
[glycine
site],L701324
[glycine
site],LY233053
[glutam
ate
site],U
BP141
[glutam
ate
site](G
luN
2D
≥
G
luN
2C
>
G
luN
2A≥
G
luN
2B)
[266],conantokin-G
[glutam
ate
site]
(G
luN
2B
>
G
luN
2D
=
G
luN
2C
=
G
luN
2A),d-AP5
[glutam
ate
site],
d-C
C
Pene
[glutam
ate
site](G
luN
2A
=
G
luN
2B
>
G
luN
2C
=
G
luN
2D
),selfotel[glutam
ate
site]
C
hannelblockers
–
M
g
2+
(G
luN
2A
=
G
luN
2B
>
G
luN
2C
=
G
luN
2D
),
N
1-dansyl-sperm
ine
(G
luN
2A
=
G
luN
2B≫
G
luN
2C
=
G
luN
2D
),
am
antidine
(G
luN
2C
=
G
luN
2D
≥
G
luN
2B≥
G
luN
2A),dizocilpine,
ketam
ine,phencyclidine
phencyclidine
(pIC
50
7.1)
[96],ketam
ine
(pIC
50
6.2)
[96],
am
antidine
(G
luN
2C
=
G
luN
2D
≥
G
luN
2B≥
G
luN
2A)
(pIC
50
4.7)
[96],M
g
2+
(G
luN
2A
=
G
luN
2B
>
G
luN
2C
=
G
luN
2D
),
N
1-dansyl-sperm
ine
(G
luN
2A
=
G
luN
2B≫
G
luN
2C
=
G
luN
2D
),
dizocilpine
Labelled
ligands
[ 3H
]M
D
L105519
[glycine
site]
(Antagonist)
(pK
d ∼
8.5)
[59]–
Rat,[ 3H
]C
G
P39653
[glutam
ate
site](Selective
Antagonist),
[ 3H
]C
G
P61594
[glycine
site]
(Antagonist),[ 3H
]C
G
S19755
[glutam
ate
site](Antagonist),
[ 3H
]C
PP
[glutam
ate
site](Selective
Antagonist),[ 3H
]L689560
[glycine
site](Antagonist),[ 3H
]dizocilpine
[cation
channel](Antagonist),
[ 3H
]glycine
[glycine
site](Agonist)
[ 3H
]C
G
P39653
[glutam
ate
site](Antagonist),[ 3H
]C
G
P61594
[glycine
site](Antagonist),[ 3H
]C
G
S19755
[glutam
ate
site]
(Antagonist),[ 3H
]C
PP
[glutam
ate
site](Antagonist),[ 3H
]L689560
[glycine
site](Antagonist),[ 3H
]M
D
L105519
[glycine
site]
(Antagonist),[ 3H
]dizocilpine
[cation
channel](C
hannelblocker),
[ 3H
]glycine
[glycine
site](Agonist)
[ 3H
]C
G
P39653
[glutam
ate
site](Antagonist),[ 3H
]C
G
P61594
[glycine
site](Antagonist),[ 3H
]C
G
S19755
[glutam
ate
site]
(Antagonist),[ 3H
]C
PP
[glutam
ate
site](Antagonist),[ 3H
]L689560
[glycine
site](Antagonist),[ 3H
]M
D
L105519
[glycine
site]
(Antagonist),[ 3H
]dizocilpine
[cation
channel](C
hannelblocker),
[ 3H
]glycine
[glycine
site](Agonist)
N
om
enclature
G
luN
3A
G
luN
3B
H
G
N
C
,U
niProt
G
RIN
3A,Q
8TC
U
5
G
RIN
3B,O
60391
C
om
m
ents
See
the
m
ain
com
m
ents
section
below
for
inform
ation
on
the
pharm
acology
ofG
luN
3A
and
G
luN
3B
subunits
Searchable
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C
o
m
m
en
ts:N
M
D
A
recep
to
rs
Poten
cy
orders
un
referen
ced
in
th
e
table
are
from
[62,
96,
106,
212,
290,
365].
In
addition
to
th
e
glutam
ate
an
d
glycin
e
bin
d-
in
g
sites
docum
en
ted
in
th
e
table,
ph
ysiologically
im
portan
t
in
-
h
ibitory
m
odulatory
sites
exist
for
M
g
2+,
Zn
2+,
an
d
proton
s
[74,
86,
365].
V
oltage-in
depen
den
t
in
h
ibition
by
Zn
2+
bin
din
g
w
ith
h
igh
affin
ity
w
ith
in
th
e
A
TD
is
h
igh
ly
subun
it
selective
(G
luN
2A
≫
G
luN
2B
>
G
luN
2C
≥
G
luN
2D
;[290,365]).Th
e
receptor
is
also
allosterically
m
odulated,in
both
positive
an
d
n
egative
direction
s,
by
en
dogen
ous
n
euroactive
steroids
in
a
subun
it
depen
den
t
m
an
-
n
er[153,239].Ton
ic
proton
blockade
ofN
M
D
A
receptorfun
ction
is
alleviated
by
polyam
in
es
an
d
th
e
in
clusion
of
exon
5
w
ith
in
G
luN
1
subun
it
splice
varian
ts,
w
h
ereas
th
e
n
on
-com
petitive
an
-
tagon
ists
ifen
prodil
an
d
traxoprodil
in
crease
th
e
fraction
of
re-
ceptors
blocked
by
proton
s
at
am
bien
t
con
cen
tration
.
In
clusion
of
exon
5
also
abolish
es
poten
tiation
by
polyam
in
es
an
d
in
h
i-
bition
by
Zn
2+
th
at
occurs
th
rough
bin
din
g
in
th
e
A
TD
[364].
Ifen
prodil,traxoprodil,h
aloperidol,felbam
ate
an
d
R
o
8-4304
dis-
crim
in
ate
betw
een
recom
bin
an
t
N
M
D
A
receptors
assem
bled
from
G
luN
1
an
d
eith
er
G
luN
2A
,
or
G
luN
2B,
subun
its
by
actin
g
as
se-
lective,n
on
-com
petitive,an
tagon
ists
ofh
eterooligom
ers
in
corpo-
ratin
g
G
luN
2B
th
rough
a
bin
din
g
site
at
th
e
A
TD
G
luN
1/G
luN
2B
subun
it
in
terface
[187].
LY
233536
is
a
com
petitive
an
tagon
ist
th
at
also
displays
selectivity
for
G
luN
2B
over
G
luN
2A
subun
it-
con
tain
in
g
receptors.
Sim
ilarly,
C
G
P61594
is
a
ph
otoaffin
ity
la-
belth
at
in
teracts
selectively
w
ith
receptors
in
corporatin
g
G
luN
2B
versus
G
luN
2A
,
G
luN
2D
an
d,
to
a
lesser
exten
t,
G
luN
2C
sub-
un
its.
TC
N
201
an
d
TC
N
213
h
ave
recen
tly
been
sh
ow
n
to
block
G
luN
2A
N
M
D
A
receptors
selectively
by
a
m
ech
an
ism
th
at
in
-
volves
allosteric
in
h
ibition
of
glycin
e
bin
din
g
to
th
e
G
luN
1
site
[29,
101,
136,
248].
In
addition
to
in
fluen
cin
g
th
e
ph
arm
aco-
logical
profile
of
th
e
N
M
D
A
receptor,
th
e
iden
tity
of
th
e
G
luN
2
subun
it
co-assem
bled
w
ith
G
luN
1
is
an
im
portan
t
determ
in
an
t
of
bioph
ysical
properties
th
at
in
clude
sen
sitivity
to
block
by
M
g
2+,
sin
gle-ch
an
n
el
con
ductan
ce
an
d
m
axim
al
open
probablity
an
d
ch
an
n
el
deactivation
tim
e
[74,
105,
123].
In
corporation
of
th
e
G
luN
3A
subun
itin
to
tri-h
eterom
erscon
tain
in
g
G
luN
1
an
d
G
luN
2
subun
its
is
associated
w
ith
decreased
sin
gle-ch
an
n
elcon
ductan
ce,
reduced
perm
eability
to
C
a 2+
an
d
decreased
susceptibility
to
block
by
M
g
2+
[52,142].R
educed
perm
eability
to
C
a 2+
h
asalso
been
ob-
served
follow
in
g
th
e
in
clusion
of
G
luN
3B
in
tri-h
eterom
ers.
Th
e
expression
of
G
luN
3A
,
or
G
luN
3B,
w
ith
G
luN
1
alon
e
form
s,
in
X
enopus
laevis
oocytes,
a
cation
ch
an
n
el
w
ith
un
ique
properties
th
at
in
clude
activation
by
glycin
e
(but
n
ot
N
M
D
A
),
lack
of
per-
m
eation
by
C
a 2+
an
d
resistan
ce
to
blockade
by
M
g
2+
an
d
N
M
D
A
receptor
an
tagon
ists
[56].
Th
e
fun
ction
of
h
eterom
ers
com
posed
of
G
luN
1
an
d
G
luN
3A
is
en
h
an
ced
by
Zn
2+,
or
glycin
e
site
an
-
tagon
ists,bin
din
g
to
th
e
G
luN
1
subun
it
[236].
Zn
2+
also
directly
activates
such
com
plexes.
Th
e
co-expression
of
G
luN
1,
G
luN
3A
an
d
G
luN
3B
appears
to
be
required
to
form
glycin
e-activated
re-
ceptors
in
m
am
m
alian
cellh
osts
[339].
A
M
PA
an
d
K
ain
ate
recep
to
rs
A
ll
A
M
PA
receptors
are
addition
ally
activated
by
kain
ate
(an
d
dom
oic
acid)
w
ith
relatively
low
poten
cy,(EC
50 ˜100
µ
M
).In
clu-
sion
of
TA
R
Ps
w
ith
in
th
e
receptor
com
plex
in
creases
th
e
poten
cy
an
d
m
axim
al
effect
of
kain
ate
[165,
260].
A
M
PA
is
w
eak
partial
agon
ist
at
G
luK
1
an
d
at
h
eterom
eric
assem
blies
of
G
luK
1/G
luK
2,
G
luK
1/G
luK
5
an
d
G
luK
2/G
luK
5
[171].
Q
uin
oxalin
edion
es
such
as
C
N
Q
X
an
d
N
BQ
X
sh
ow
lim
ited
selectivity
betw
een
A
M
PA
an
d
kain
ate
receptors.
Tezam
pan
el
also
h
as
kain
ate
(G
luK
1)
receptor
activity
as
h
as
G
Y
K
I53655
(G
luK
3
an
d
G
luK
2/G
luK
3)[171].A
TPO
isa
poten
tcom
petitive
an
tagon
istofA
M
PA
receptors,h
asa
w
eaker
an
tagon
istaction
atkain
ate
receptors
com
prisin
g
G
luK
1
subun
its,
but
is
devoid
of
activity
at
kain
ate
receptors
form
ed
from
G
luK
2
or
G
luK
2/G
luK
5
subun
its.
Th
e
ph
arm
acologicalactivity
of
A
TPO
resides
w
ith
th
e
(S)-en
an
tiom
er.
A
C
ET
an
d
U
BP310
m
ay
block
G
luK
3,in
addition
to
G
luK
1
[13,299].(2S,4R
)-4-m
eth
ylglutam
ate
(SY
M
2081)
is
equipoten
t
in
activatin
g
(an
d
desen
sitisin
g)
G
luK
1
an
d
G
luK
2
receptor
isoform
s
an
d,via
th
e
in
duction
of
desen
siti-
sation
atlow
con
cen
tration
s,h
as
been
used
as
a
fun
ction
alan
tag-
on
ist
of
kain
ate
receptors.
Both
(2S,4R)-4-m
eth
ylglutam
ate
an
d
LY
339434
h
ave
agon
ist
activity
at
N
M
D
A
receptors.
(2S,4R
)-4-
m
eth
ylglutam
ate
is
also
an
in
h
ibitorofth
e
glutam
ate
tran
sporters
EA
A
T1
an
d
EA
A
T2.
D
elta
su
b
u
n
its
G
luD
1
an
d
G
luD
2
com
prise,on
th
e
basis
of
sequen
ce
h
om
ology,
an
‘orph
an
’class
of
ion
otropic
glutam
ate
receptor
subun
it.
Th
ey
do
n
ot
form
a
fun
ction
al
receptor
w
h
en
expressed
solely,
or
in
com
bin
ation
w
ith
oth
er
ion
otropic
glutam
ate
receptor
subun
its,
in
tran
sfected
cells
[403].H
ow
ever,G
luD
2
subun
its
bin
d
D
-serin
e
an
d
glycin
e
an
d
G
luD
2
subun
its
carryin
g
th
e
m
utation
A
654T
form
a
spon
tan
eously
open
ch
an
n
el
th
at
is
closed
by
D
-serin
e
[272].
Fu
rth
er
read
in
g
o
n
Io
n
o
tro
p
ic
g
lu
tam
ate
recep
to
rs
Filippin
i,A
et
al.
(2016)
Th
e
G
ood
an
d
th
e
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G
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R
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R
N
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M
olN
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[PM
ID
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G
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A
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s.N
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[PM
ID
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H
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H
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D
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M
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s
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con
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ces.
N
europharm
acology
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[PM
ID
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K
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G
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IP
3
receptor
Ligan
d-gated
ion
ch
an
n
els→
IP
3
receptor
O
verview
:
Th
e
in
ositol
1,4,5-trisph
osph
ate
receptors
(IP
3 R
)
are
ligan
d-gated
C
a 2+-release
ch
an
n
els
on
in
tracellular
C
a2+
store
sites
(such
as
th
e
en
doplasm
ic
reticulum
).
Th
ey
are
respon
sible
for
th
e
m
obilization
of
in
tracellular
C
a 2+
stores
an
d
play
an
im
portan
t
role
in
in
tracellular
C
a 2+
sign
allin
g
in
a
w
ide
variety
of
cell
types.
Th
ree
differen
t
gen
e
products
(types
I–III)
h
ave
been
isolated,
w
h
ich
assem
ble
as
large
tetram
eric
structures.
IP
3 R
s
are
closely
associated
w
ith
certain
protein
s:
calm
odulin
(
C
A
LM
1
C
A
LM
2
C
A
LM
3,P62158)
an
d
FK
BP
(an
d
calcin
eurin
via
FK
BP).Th
ey
are
ph
osph
orylated
by
PK
A
,PK
C
,PK
G
an
d
C
aM
K
II.
N
om
enclature
IP
3 R1
IP
3 R2
IP
3 R3
H
G
N
C
,U
niProt
ITPR1,Q
14643
ITPR2,Q
14571
ITPR3,Q
14573
Endogenous
activators
cytosolic
ATP
(<
m
M
range),cytosolic
C
a 2+
C
oncentration
range:
¡7.5×
10 −
4M
,IP
3
(endogenous;nM
-µ
M
range)
cytosolic
C
a 2+
(nM
range),IP
3
(endogenous;nM
-µ
M
range)
cytosolic
C
a 2+
(nM
range),IP
3
(endogenous;nM
-µ
M
range)
Activators
adenophostin
A
(pharm
acological;nM
range),
inositol2,4,5-trisphosphate
(pharm
acological;also
activated
by
other
InsP
3
analogues)
adenophostin
A
(pharm
acological;nM
range),
inositol2,4,5-trisphosphate
(pharm
acological;also
activated
by
other
InsP
3
analogues)
–
Antagonists
PIP
2
(µ
M
range),caffeine
(m
M
range),decavanadate
(µ
M
range),
xestospongin
C
(µ
M
range)
decavanadate
(µ
M
range)
decavanadate
(µ
M
range)
FunctionalC
haracteristics
C
a 2+:(P
Ba /P
K ˜6)
single-channelconductance
˜70
pS
(50
m
M
C
a 2+)
C
a 2+:single-channelconductance
˜70
pS
(50
m
M
C
a 2+)
˜390
pS
(220
m
M
C
s +)
C
a 2+:single-channel
conductance
˜88
pS
(55
m
M
Ba 2+)
C
om
m
ents
IP
3
R1
is
also
antagonised
by
calm
odulin
at
high
cytosolic
C
a 2+
concentrations
–
–
C
o
m
m
en
ts:Th
e
absen
ce
of
a
m
odulator
of
a
particular
isoform
of
receptor
in
dicates
th
at
th
e
action
of
th
at
m
odulator
h
as
n
ot
been
determ
in
ed,n
ot
th
at
it
is
w
ith
out
effect.
Fu
rth
er
read
in
g
o
n
IP
3
recep
to
r
Berridge
M
J.(2016)
Th
e
In
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osph
ate/C
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Sign
alin
g
Path
w
ay
in
H
ealth
an
d
D
isease.
PhysiolRev
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[PM
ID
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G
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M
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C
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A
cta
1864
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907-914
[PM
ID
:27884701]
M
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O
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osph
ate
receptors
in
th
e
en
doplasm
ic
reticulum
:A
sin
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t
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allin
g
h
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[PM
ID
:26830355]
Seo
M
D
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d
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N
icotinic
acetylcholine
receptors
Ligan
d-gated
ion
ch
an
n
els→
N
icotin
ic
acetylch
olin
e
receptors
O
verview
:
N
icotin
ic
acetylch
olin
e
receptors
are
m
em
bers
of
th
e
C
ys-loop
fam
ily
of
tran
sm
itter-gated
ion
ch
an
n
els
th
at
in
cludes
th
e
G
A
BA
A
,
strych
n
in
e-sen
sitive
glycin
e
an
d
5-H
T
3
receptors
[6,
257,334,350,387].A
lln
icotin
ic
receptorsare
pen
tam
ersin
w
h
ich
each
of
th
e
five
subun
its
con
tain
s
four
α
-h
elical
tran
sm
em
bran
e
dom
ain
s.
G
en
es
en
codin
g
a
totalof
17
subun
its
(α
1-10,β1-4,γ,δ
an
d
ϵ)h
ave
been
iden
tified
[185].A
llsubun
its
w
ith
th
e
exception
ofα
8
(presen
t
in
avian
species)h
ave
been
iden
tified
in
m
am
m
als.
A
ll
α
subun
its
possess
tw
o
tan
dem
cystein
e
residues
n
ear
to
th
e
site
in
volved
in
acetylch
olin
e
bin
din
g,
an
d
subun
its
n
ot
n
am
ed
α
lack
th
ese
residues
[257].
Th
e
orth
osteric
ligan
d
bin
din
g
site
is
form
ed
by
residues
w
ith
in
atleastth
ree
peptide
dom
ain
s
on
th
e
α
subun
it(prin
cipalcom
pon
en
t),an
d
th
ree
on
th
e
adjacen
tsubun
it
(com
plem
en
tary
com
pon
en
t).
n
A
C
h
R
s
con
tain
several
allosteric
m
odulatory
sites.O
n
e
such
site,for
positive
allosteric
m
odulators
(PA
M
s)an
d
allosteric
agon
ists,h
as
been
proposed
to
reside
w
ith
in
an
in
trasubun
it
cavity
betw
een
th
e
four
tran
sm
em
bran
e
dom
ain
s
[124,
401];
see
also
[144]).
Th
e
h
igh
resolution
crystal
structure
of
th
e
m
olluscan
acetylch
olin
e
bin
din
g
protein
,
a
structural
h
o-
m
ologue
ofth
e
extracellular
bin
din
g
dom
ain
ofa
n
icotin
ic
recep-
tor
pen
tam
er,
in
com
plex
w
ith
several
n
icotin
ic
receptor
ligan
ds
(e.g.[53])
an
d
th
e
crystal
structure
of
th
e
extracellular
dom
ain
of
th
e
α
1
subun
itboun
d
to
α
-bun
garotoxin
at1.94
Å
resolution
[82],
h
as
revealed
th
e
orth
osteric
bin
din
g
site
in
detail(review
ed
in
[55,
185,
315,
334]).
N
icotin
ic
receptors
at
th
e
som
atic
n
eurom
uscu-
lar
jun
ction
of
adult
an
im
als
h
ave
th
e
stoich
iom
etry
(α
1)2 β1δϵ,
w
h
ereas
an
extrajun
ction
al
(α
1)2 β1γδ
receptor
predom
in
ates
in
em
bryon
ic
an
d
den
ervated
skeletalm
uscle
an
d
oth
erpath
ological
states.O
th
ern
icotin
ic
receptors
are
assem
bled
as
com
bin
ation
s
of
α
(2-6)an
d
β(2-4)subun
its.Forα
2,α
3,α
4
an
d
β2
an
d
β4
subun
its,
pairw
ise
com
bin
ation
s
of
α
an
d
β
(e.g.
α
3β4
an
d
α
4β2)
are
suffi-
cien
t
to
form
a
fun
ction
alreceptor
in
vitro,but
far
m
ore
com
plex
isoform
s
m
ay
exist
in
vivo
(review
ed
in
[127,
128,
257]).
Th
ere
is
stron
g
eviden
ce
th
at
th
e
pairw
ise
assem
bly
of
som
e
α
an
d
β
subun
its
can
occur
w
ith
variable
stoich
iom
etry
[e.g.(α
4)2 (β2)2
or
(α
4)3 (β2)2 ]w
h
ich
in
fluen
cesth
e
bioph
ysicalan
d
ph
arm
acological
properties
ofth
e
receptor
[257].α
5
an
d
β3
subun
its
lack
fun
ction
w
h
en
expressed
alon
e,
or
pairw
ise,
but
participate
in
th
e
form
a-
tion
of
fun
ction
alh
etero-oligom
eric
receptors
w
h
en
expressed
as
a
th
ird
subun
itw
ith
an
oth
erα
an
d
β
pair[e.g.α
4α
5αβ2,α
4αβ2β3,
α
5α
6β2,see
[257]for
furth
er
exam
ples].Th
e
α
6
subun
it
can
form
a
fun
ction
alreceptorw
h
en
co-expressed
w
ith
β4
in
vitro,butm
ore
efficien
t
expression
en
sues
from
in
corporation
of
a
th
ird
partn
er,
such
as
β3
[391].
Th
e
α
7,
α
8,
an
d
α
9
subun
its
form
fun
ction
al
h
om
o-oligom
ers,but
can
also
com
bin
e
w
ith
a
secon
d
subun
it
to
con
stitute
a
h
etero-oligom
eric
assem
bly
(e.g.
α
7β2
an
d
α
9α
10).
For
fun
ction
al
expression
of
th
e
α
10
subun
it,
co-assem
bly
w
ith
α
9
is
n
ecessary.Th
e
latter,alon
g
w
ith
th
e
α
10
subun
it,appears
to
be
largely
con
fin
ed
to
coch
lear
an
d
vestibular
h
air
cells.C
om
pre-
h
en
sive
listin
gs
of
n
icotin
ic
receptor
subun
it
com
bin
ation
s
iden
-
tified
from
recom
bin
an
t
expression
system
s,
or
in
vivo,
are
given
in
[257].
In
addition
,
n
um
erous
protein
s
in
teract
w
ith
n
icotin
ic
A
C
h
receptors
m
odifyin
g
th
eir
assem
bly,
traffickin
g
to
an
d
from
th
e
cellsurface,an
d
activation
by
A
C
h
(review
ed
by
[9,183,256]).
Th
e
n
icotin
ic
receptor
Subcom
m
ittee
ofN
C
-IU
P
H
A
R
h
as
recom
-
m
en
ded
a
n
om
en
clature
an
d
classification
sch
em
e
for
n
icotin
ic
acetylch
olin
e
(n
A
C
h
)receptors
based
on
th
e
subun
itcom
position
of
kn
ow
n
,
n
aturally-
an
d/or
h
eterologously-expressed
n
A
C
h
re-
ceptorsubtypes
[230].H
eadin
gs
forth
is
table
reflectabbreviation
s
design
atin
g
n
A
C
h
receptor
subtypes
based
on
th
e
predom
in
an
tα
subun
it
con
tain
ed
in
th
at
receptor
subtype.A
n
asterisk
follow
in
g
th
e
in
dicated
α
subun
itden
otes
th
atoth
er
subun
its
are
kn
ow
n
to,
or
m
ay,assem
ble
w
ith
th
e
in
dicated
α
subun
it
to
form
th
e
desig-
n
ated
n
A
C
h
receptor
subtype(s).
W
h
ere
subun
it
stoich
iom
etries
w
ith
in
a
specific
n
A
C
h
receptor
subtype
are
kn
ow
n
,
n
um
bers
of
a
particular
subun
it
larger
th
an
1
are
in
dicated
by
a
subscript
fol-
low
in
g
th
e
subun
it
(en
closed
in
paren
th
eses
–
see
also
[71]).
N
om
enclature
nicotinic
acetylcholine
receptorα
1
subunit
nicotinic
acetylcholine
receptorα
2
subunit
nicotinic
acetylcholine
receptorα
3
subunit
nicotinic
acetylcholine
receptorα
4
subunit
H
G
N
C
,U
niProt
CH
RN
A1,P02708
CH
RN
A2,Q
15822
CH
RN
A3,P32297
CH
RN
A4,P43681
C
om
m
only
used
antagonists
(α
1)2 β1γδ
and
(α
1)2 β1δϵ:α
-bungarotoxin
>
pancuronium
>
vecuronium
>
rocuronium
>
tubocurarine
(IC
50
=
43
-
82
nM
)
α
2β2:D
H
βE
(K
B
=
0.9
µ
M
),tubocurarine
(K
B
=
1.4
µ
M
);α
2β4:D
H
βE
(K
B
=
3.6
µ
M
),tubocurarine
(K
B
=
4.2
µ
M
)
α
3β2:D
H
βE
(K
B
=
1.6
µ
M
,IC
50
=
2.0
µ
M
),tubocurarine
(K
B
=
2.4
µ
M
);α
3β4:
D
H
βE
(K
B
=
19
µ
M
,IC
50
=
26
µ
M
),
tubocurarine
(K
B
=
2.2
µ
M
)
α
4β2:D
H
βE
(K
B
=
0.1
µ
M
;IC
50
=
0.08
-0.9
µ
M
),tubocurarine
(K
B
=
3.2
µ
M
,IC
50
=
34
µ
M
);α
4β4:D
H
βE
(K
B
=
0.01
µ
M
,IC
50
=
0.19
–
1.2
µ
M
),
tubocurarine
(K
B
=
0.2
µ
M
,IC
50
=
50
µ
M
)
Selective
agonists
succinylcholine
(selective
for
(α
1)2 β1γδ)
–
–
varenicline
[70],rivanicline
[91],
TC
-2559
(α
4β2)
[65]
Selective
antagonists
α
-bungarotoxin,α
-conotoxin
G
I,
α
-conotoxin
M
I,pancuronium
,w
aglerin-1
(selective
for
(α
1)2 β1δϵ)
–
α
-conotoxin
AuIB
(α
3β4),α
-conotoxin
M
II
(α
3β2),α
-conotoxin
PnIA
(α
3β2),
α
-conotoxin
TxIA
(α
3β2),α
-conotoxin-G
IC
(α
3β2)
–
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
N
icotinic
acetylcholine
receptors
S151
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13879/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:Ligand-gated
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channels.British
JournalofPharm
acology
(2017)174,S130–S159
(continued)
N
om
enclature
nicotinic
acetylcholine
receptorα
1
subunit
nicotinic
acetylcholine
receptorα
2
subunit
nicotinic
acetylcholine
receptorα
3
subunit
nicotinic
acetylcholine
receptorα
4
subunit
C
hannelblockers
gallam
ine
((α
1)2 β1γδ
and
(α
1)2 β1δϵ)
(pIC
50 ∼
6),m
ecam
ylam
ine
((α
1)2 β1δϵ)
(pIC
50 ∼
5.8)
hexam
ethonium
,m
ecam
ylam
ine
m
ecam
ylam
ine
(α
3β4)
(pIC
50
6.4),
m
ecam
ylam
ine
(α
3β2)
(pIC
50
5.1),
A-867744
(α
3β4)
[240],N
S1738
(α
3β4)
[361],hexam
ethonium
(α
3β4),
hexam
ethonium
(α
3β2)
m
ecam
ylam
ine
(α
4β4)
(pIC
50
5.3–6.5),m
ecam
ylam
ine
(α
4β2)
(pIC
50
5.4–5.4),hexam
ethonium
(α
4β2)
(pIC
50
4.5–5.2),
hexam
ethonium
(α
4β4)
(pIC
50
4),
A-867744
(α
4β2)
[240],N
S1738
(α
4β2)
[361]
Allosteric
m
odulators
–
LY2087101
(Positive)
[42]
–
LY2087101
(Positive)
[42]
Selective
allosteric
m
odulators
–
–
–
N
S9283
(Positive)
[216]
Labelled
ligands
[ 125I]α
-bungarotoxin
(Selective
Antagonist),[ 3H
]α
-bungarotoxin
(Selective
Antagonist)
[ 125I]epibatidine
(Agonist),
[ 3H
]epibatidine
(Agonist),
[ 3H
]cytisine
(Agonist)
[ 125I]epibatidine
(Agonist),[ 3H
]epibatidine
(Agonist),[ 3H
]cytisine
(Agonist)
[ 125I]epibatidine
(Agonist),
[ 3H
]epibatidine
(Agonist),[ 3H
]cytisine
(Agonist),[ 125I]epibatidine
(Agonist),
[ 3H
]epibatidine
(Agonist),[ 3H
]nicotine
(Agonist)
–
Rat,[ 3H
]cytisine
(Agonist)
FunctionalC
haracteristics
(α
1)2 βγδ:P
C
a /P
N
a
=
0.16
-0.2,Pf =
2.1
–
2.9%
;(α
1)2 βδϵ:P
C
a /P
N
a
=
0.65
–
1.38,Pf
=
4.1
–
7.2%
α
2β2:P
C
a /P
N
a ˜1.5
α
3β2:P
C
a /P
N
a
=
1.5;α
3β4:P
C
a /P
N
a
=
0.78
-1.1,Pf =
2.7
–
4.6%
α
4β2:P
C
a /P
N
a
=
1.65,Pf =
2.6
–
2.9%
;α
4β4:Pf =
1.5
–
3.0
%
N
om
enclature
nicotinic
acetylcholine
receptorα
5
subunit
nicotinic
acetylcholine
receptorα
6
subunit
nicotinic
acetylcholine
receptorα
7
subunit
H
G
N
C
,U
niProt
CH
RN
A5,P30532
CH
RN
A6,Q
15825
CH
RN
A7,P36544
C
om
m
only
used
antagonists
–
α
6/α
3β2β3
chim
era:D
H
βE
(IC
50
=
1.1
µ
M
)
(α
7)5 :D
H
βE
(IC
50
=
8
-20
µ
M
);(α
7)5 :tubocurarine
(IC
50
=
3.1
µ
M
)
Selective
agonists
–
–
encenicline
(Partialagonist)
[247,280],AQ
W
051
([125I]α
-bungarotoxin
binding
assay)
[167],4BP-TQ
S
(allosteric)
[124],A-582941
((α
7)5 )
[33],PH
A-543613
((α
7)5 )
[385],PH
A-709829
((α
7)5 )
[2],PN
U
-282987
((α
7)5 )
[36],bradanicline
((α
7)5 )
[139]
Selective
antagonists
α
-conotoxin
M
II,α
-conotoxin
PnIA,α
-conotoxin
TxIA,
α
-conotoxin-G
IC
α
-conotoxin
M
II(α
6β2*),α
-conotoxin
M
II[H
9A,L15A]
(α
6β2β3),α
-conotoxin
PIA
(α
6/α
3β2β3
chim
era)
α
-bungarotoxin
((α
7)5 ),α
-conotoxin
ArIB
((α
7)5 ),
α
-conotoxin
Im
I((α
7)5 ),m
ethyllycaconitine
((α
7)5 )
C
hannelblockers
–
m
ecam
ylam
ine
(α
6/α
3β2β3
chim
era)
(pIC
50
5),
hexam
ethonium
(α
6/α
3β2β3
chim
era)
(pIC
50
4)
m
ecam
ylam
ine
((α
7)5 )
(pIC
50
4.8)
Allosteric
m
odulators
–
–
A-867744
(Positive)
[240],LY2087101
(Positive)
[42],
N
S1738
(Positive)
[361]
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
N
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acetylcholine
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FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
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N
om
enclature
nicotinic
acetylcholine
receptorα
5
subunit
nicotinic
acetylcholine
receptorα
6
subunit
nicotinic
acetylcholine
receptorα
7
subunit
Selective
allosteric
m
odulators
–
–
JN
J1930942
(Positive)
[87],PN
U
-120596
(Positive)
[161]
Labelled
ligands
–
[ 3H
]epibatidine
(Agonist)
–
C
hicken,
[ 125I]α
-conotoxin
M
II(Antagonist)
[ 3H
]epibatidine
(Agonist),[ 3H
]A-585539
(Agonist)
[7],
[ 3H
]AZ11637326
(Agonist)
[126],[ 125I]α
-bungarotoxin
(Selective
Antagonist)
(pK
d
8.3–9.1),
[ 3H
]α
-bungarotoxin
(Selective
Antagonist)
(pK
d
8.3–9.1),[ 3H
]m
ethyllycaconitine
(Antagonist)
(pK
d
8.7)
–
Rat
FunctionalC
haracteristics
–
–
P
C
a /P
N
a
=
6.6-20,Pf =
8.8
-11.4%
N
om
enclature
nicotinic
acetylcholine
receptorα
8
subunit
(avian)
nicotinic
acetylcholine
receptorα
9
subunit
nicotinic
acetylcholine
receptorα
10
subunit
H
G
N
C
,U
niProt
–
CH
RN
A9,Q
9U
G
M
1
CH
RN
A10,Q
9G
ZZ6
C
om
m
only
used
antagonists
(α
8)5 :α
-bungarotoxin
>
atropine≥
tubocurarine≥
strychnine
(α
9)5 :α
-bungarotoxin
>
m
ethyllycaconitine
>
strychnine˜tropisetron
>
tubocurarine;α
9α
10:
α
-bungarotoxin
>
tropisetron
=
strychnine
>
tubocurarine
α
9α
10:α
-bungarotoxin
>
tropisetron
=
strychnine
>
tubocurarine
Selective
antagonists
–
α
-bungarotoxin
((α
9)5 ),α
-bungarotoxin
(α
9α
10),
α
-conotoxin
RgIA
(α
9α
10),m
uscarine
((α
9)5 ),
m
uscarine
(α
9α
10),nicotine
((α
9)5 ),nicotine
(α
9α
10),
strychnine
((α
9)5 ),strychnine
(α
9α
10)
α
-bungarotoxin
(α
9α
10),α
-conotoxin
RgIA
(α
9α
10),
m
uscarine
(α
9α
10),nicotine
(α
9α
10),strychnine
(α
9α
10)
Labelled
ligands
[ 3H
]epibatidine
((α
8)5 )
(pK
d
9.7),[ 125I]α
-bungarotoxin
(native
α
8*)
(pK
d
8.3),[ 3H
]α
-bungarotoxin
(native
α
8*)
(pK
d
8.3)
[ 3H
]m
ethyllycaconitine
(Antagonist)
(pK
d
8.1),
[ 125I]α
-bungarotoxin
(Antagonist),[ 3H
]α
-bungarotoxin
(Antagonist)
[ 3H
]m
ethyllycaconitine
(Antagonist)
(pK
d
8.1)
FunctionalC
haracteristics
–
(α
9)5 :P
C
a /P
N
a
=
9;α
9α
10:P
C
a /P
N
a
=
9,Pf =
22%
α
9α
10:P
C
a /P
N
a
=
9,Pf =
22%
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
N
icotinic
acetylcholine
receptors
S153
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13879/full
S.P.H.Alexanderetal.The
Concise
Guide
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N
om
enclature
nicotinic
acetylcholine
receptorβ1
subunit
nicotinic
acetylcholine
receptorβ2
subunit
nicotinic
acetylcholine
receptorβ3
subunit
nicotinic
acetylcholine
receptorβ4
subunit
nicotinic
acetylcholine
receptorγ
subunit
nicotinic
acetylcholine
receptor
δ
subunit
nicotinic
acetylcholine
receptor
ϵ
subunit
H
G
N
C
,U
niProt
CH
RN
B1,P11230
CH
RN
B2,P17787
CH
RN
B3,Q
05901
CH
RN
B4,P30926
CH
RN
G
,P07510
CH
RN
D
,Q
07001
CH
RN
E,Q
04844
Antagonists
–
–
–
–
–
PhTX
-11
(pIC
50
6.2–6.3)
[346]
–
C
om
m
ents
Ligand
interaction
data
for
hetero-oligom
eric
receptors
containing
the
β1
receptors
are
listed
under
the
α
1
receptors.
C
o
m
m
en
ts:
C
om
m
on
ly
used
agon
ists
of
n
A
C
h
receptors
th
at
display
lim
ited
discrim
in
ation
in
fun
ction
al
assays
betw
een
re-
ceptor
subtypes
in
clude
A
-85380,
cytisin
e,
D
M
PP,
epibatidin
e,
n
icotin
e
an
d
th
e
n
aturaltran
sm
itter,acetylch
olin
e
(A
C
h
).A
sum
-
m
ary
ofth
eir
profile
across
differin
g
receptors
is
provided
in
[128]
an
d
quan
titative
data
across
n
um
erous
assay
system
s
are
sum
m
a-
rized
in
[177].
Q
uan
titative
data
presen
ted
in
th
e
table
for
com
-
m
on
ly
used
an
tagon
istsan
d
ch
an
n
elblockersforh
um
an
receptors
studied
un
dervoltage-clam
p
are
from
[46,58,291,292,295,386].
Type
I
PA
M
s
in
crease
peak
agon
ist-evoked
respon
ses
but
h
ave
lit-
tle,or
n
o,effecton
th
e
rate
ofdesen
sitization
ofα
7
n
icotin
ic
A
C
h
receptors
w
h
ereas
type
II
PA
M
s
also
cause
a
large
reduction
in
de-
sen
sitization
(review
ed
in
[384]).
Fu
rth
er
read
in
g
o
n
N
ico
tin
ic
acetylch
o
lin
e
recep
to
rs
A
uerbach
,A
.(2015)A
gon
istactivation
ofa
n
icotin
ic
acetylch
olin
e
receptor.N
europharm
acology
96
:
150-6
[PM
ID
:25446670]
Bertran
d,D
et
al.
(2015)
Th
erapeutic
Poten
tial
of
alph
a7
N
icotin
ic
A
cetylch
olin
e
R
eceptors.
Phar-
m
acolRev
67
:1025-1073
[PM
ID
:26419447]
Bouzat,C
et
al.
(2017)
N
icotin
ic
acetylch
olin
e
receptors
at
th
e
sin
gle-ch
an
n
ellevel.
Br
J
Pharm
acol
[PM
ID
:28261794]
C
h
atzidaki,A
etal.(2015)A
llosteric
m
odulation
ofn
icotin
ic
acetylch
olin
e
receptors.Biochem
Phar-
m
acol97
:408-17
[PM
ID
:26231943]
C
orradi,
J
et
al.
(2016)
U
n
derstan
din
g
th
e
Bases
of
Fun
ction
an
d
M
odulation
of
alph
a7
N
icotin
ic
R
eceptors:Im
plication
s
for
D
rug
D
iscovery.M
olPharm
acol90
:288-99
[PM
ID
:27190210]
C
respi,
A
et
al.
(2017)
Protein
s
an
d
ch
em
ical
ch
aperon
es
in
volved
in
n
euron
al
n
icotin
ic
receptor
expression
an
d
fun
ction
:an
update.Br
JPharm
acol[PM
ID
:28294298]
D
in
eley,
K
T
et
al.
(2015)
N
icotin
ic
A
C
h
receptors
as
th
erapeutic
targets
in
C
N
S
disorders.
Trends
Pharm
acolSci36
:96-108
[PM
ID
:25639674]
Lukas,
R
J
et
al.
(1999)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
X
X
.
C
urren
t
status
of
th
e
n
om
en
-
clature
for
n
icotin
ic
acetylch
olin
e
receptors
an
d
th
eir
subun
its.
Pharm
acol
Rev
51
:
397-401
[PM
ID
:10353988]
Stokes,C
et
al.
(2015)
Lookin
g
below
th
e
surface
of
n
icotin
ic
acetylch
olin
e
receptors.
Trends
Phar-
m
acolSci36
:514-23
[PM
ID
:26067101]
W
an
g,
J
et
al.
(2017)
O
rth
osteric
an
d
allosteric
poten
tiation
of
h
eterom
eric
n
euron
al
n
icotin
ic
acetylch
olin
e
receptors.
Br
JPharm
acol[PM
ID
:28199738]
W
u,J
etal.(2016)
H
eterom
eric
alph
a7beta2
N
icotin
ic
A
cetylch
olin
e
R
eceptors
in
th
e
Brain
.Trends
Pharm
acolSci37
:562-74
[PM
ID
:27179601]
P2X
receptors
Ligan
d-gated
ion
ch
an
n
els→
P2X
receptors
O
verview
:
P2X
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
P
2X
R
ecep
to
rs
[71,
196])
h
ave
a
trim
eric
topology
[179,191,275]w
ith
tw
o
putative
TM
do-
m
ain
s,gatin
g
prim
arily
N
a +,K
+
an
d
C
a 2+,exception
ally
C
l -.Th
e
N
om
en
clature
Subcom
m
ittee
h
as
recom
m
en
ded
th
at
for
P2X
re-
ceptors,structuralcriteria
sh
ould
be
th
e
in
itialcriteria
for
n
om
en
-
clature
w
h
ere
possible.
X
-ray
crystallograph
y
in
dicates
th
at
fun
c-
tion
alP2X
receptors
are
trim
eric
an
d
th
ree
agon
ist
m
olecules
are
required
to
bin
d
to
a
sin
gle
receptor
in
order
to
activate
it
[125,
138,191,242].N
ative
receptors
m
ay
occur
as
eith
er
h
om
otrim
ers
(e.g.
P2X
1
in
sm
ooth
m
uscle)
or
h
eterotrim
ers
(e.g.
P2X
2:P2X
3
in
th
e
n
odose
gan
glion
an
d
P2X
1:P2X
5
in
m
ouse
cortical
astro-
cytes,[213].P2X
2,P2X
4
an
d
P2X
7
receptors
h
ave
been
sh
ow
n
to
form
fun
ction
alh
om
opolym
ers
w
h
ich
,in
turn
,activate
poresper-
m
eable
to
low
m
olecular
w
eigh
t
solutes
[349].
Th
e
h
em
i-ch
an
n
el
pan
n
exin
-1
h
as
been
im
plicated
in
th
e
pore
form
ation
in
duced
by
P2X
7
[298],but
n
ot
P2X
2
[57],receptor
activation
.
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N
om
enclature
P2X
1
P2X
2
P2X
3
P2X
4
P2X
5
P2X
6
P2X
7
H
G
N
C
,U
niProt
P2RX1,P51575
P2RX2,Q
9U
BL9
P2RX3,P56373
P2RX4,Q
99571
P2RX5,Q
93086
P2RX6,O
15547
P2RX7,Q
99572
Endogenous
agonists
–
ATP
[167]–
Rat
ATP
[168]
ATP
[168]
ATP
[168]–
Rat
ATP
[168]–
Rat
ATP
[168]
Agonists
αβ-m
eATP,BzATP,
L-βγ-m
eATP
–
αβ-m
eATP,BzATP
–
–
–
–
Antagonists
TN
P-ATP
(pIC
50 ∼
8.9)
[370],Ip
5 I(pIC
50
∼
8.5),N
F023
(pIC
50
∼
6.7),N
F449
(pIC
50
∼
6.3)
[195]
N
F770
(pIC
50
7–8)
[281],N
F778
(pIC
50
7–8)
[281],PSB-10211
(pIC
50 ∼
7)
[281]
TN
P-ATP
(pIC
50 ∼
8.9)
[370],AF-906
(pIC
50
8.9)
[170],AF-219
(pIC
50
8.5)
[170],
A317491
(pIC
50 ∼
7.5)
[173]
5-BD
BD
(pIC
50
5–6)
[170,
281],BX
-430
(pIC
50
5–6)
[170,281],PSB-12062
(pIC
50
5–6)
[170,281],
paroxetine
(pIC
50
5–6)
[175,281]
–
–
AZ10606120
(pK
d
8.9)
[250],
A804598
(pIC
50 ∼
8),
brilliant
blue
G
(pIC
50 ∼
8)
[180],A839977
(pIC
50 ∼
7.7)
[93,95,149],A740003
(pIC
50
7.4)
[150],
decavanadate
(pA
2
=
7.4)
(pA
2
7.4)
[255],A438079
(pIC
50 ∼
6.9)
[93],
AZ11657312
(salt
free)
(pA
2
6.1)
[11]
Selective
antagonists
–
–
–
–
–
–
JN
J-479655
(pK
i 7.9)
[31]
Allosteric
m
odulators
–
–
–
–
–
–
AZ10606120
(N
egative)
[250],G
W
791343
(Positive)
[250,252]–
Rat,G
W
791343
(N
egative)
[250,252]
Selective
allosteric
m
odulators
M
RS
2219
(Positive)
[169]
–
–
iverm
ectin
(Positive)
(pEC
50 ∼
6.6)
[197]–
Rat
–
–
chelerythrine
(N
egative)
(pIC
50
5.2)
[329],
AZ11645373
(N
egative)
[253,
345],KN
62
(N
egative)
[122,
329],iverm
ectin
(Positive)
[283]
C
om
m
ents
–
–
–
–
–
–
Effects
ofthe
allosteric
m
odulators
at
P2X
7
receptors
are
species-dependent.
C
o
m
m
en
ts:
A
317491
an
d
R
O
3
also
block
th
e
P2X
2:P2X
3
h
et-
erom
ultim
er
[113,173].N
F449,A
317491
an
d
R
O
3
are
m
ore
th
an
10-fold
selective
for
P2X
1
an
d
P2X
3
receptors,respectively.
A
gon
ists
listed
sh
ow
selectivity
w
ith
in
recom
bin
an
tP2X
receptors
of
ca.
on
e
order
of
m
agn
itude.
A
804598,A
839977,A
740003
an
d
A
438079
are
atleast10-fold
selective
forP2X
7
receptors
an
d
sh
ow
sim
ilar
affin
ity
across
h
um
an
an
d
roden
t
receptors
[93,95,149].
Several
P2X
receptors
(particularly
P2X
1
an
d
P2X
3)
m
ay
be
in
-
h
ibited
by
desen
sitisation
usin
g
stable
agon
ists
(e.g.
αβ-m
eA
TP);
suram
in
an
d
PPA
D
S
are
n
on
-selective
an
tagon
ists
at
rat
an
d
h
u-
m
an
P2X
1–3,5
an
d
h
P2X
4,
but
n
ot
rP2X
4,6,7
[45],
an
d
can
also
in
h
ibit
A
TPase
activity
[72].
Ip
5 I
is
in
active
at
rP2X
2,
an
an
-
tagon
ist
at
rP2X
3
(pIC
50
5.6)
an
d
en
h
an
ces
agon
ist
respon
ses
at
rP2X
4
[199].
A
n
tagon
ist
poten
cy
of
N
F023
at
recom
bin
an
t
P2X
2,
P2X
3
an
d
P2X
5
is
tw
o
orders
of
m
agn
itude
low
er
th
an
th
at
at
P2X
1
receptors
[342].
Th
e
P2X
7
receptor
m
ay
be
in
-
h
ibited
in
a
n
on
-com
petitive
m
an
n
er
by
th
e
protein
kin
ase
in
h
ibitors
K
N
62
an
d
ch
eleryth
rin
e
[329],
w
h
ile
th
e
p38
M
A
P
ki-
n
ase
in
h
ibitor
G
TPγS
an
d
th
e
cyclic
im
ide
A
Z11645373
sh
ow
a
species-depen
den
t
n
on
-com
petitive
action
[94,
253,
254,
345].
Th
e
pH
-sen
sitive
dye
used
in
culture
m
edia,
ph
en
ol
red,
is
also
reported
to
in
h
ibit
P2X
1
an
d
P2X
3
con
tain
in
g
ch
an
n
els
[200].
Som
e
recom
bin
an
t
P2X
receptors
expressed
to
h
igh
den
sity
bin
d
[ 35S]A
TPγS
an
d
[ 3H
]αβ-m
eA
TP,
alth
ough
th
e
latter
can
also
bin
d
to
5 ′-n
ucleotidase
[251].
[ 3H
]A
317491
an
d
[ 3H
]A
804598
h
ave
been
used
as
h
igh
affin
ity
an
tagon
ist
radioligan
ds
for
P2X
3
(an
d
P2X
2/3)
an
d
P2X
7
receptors,respectively
[95].
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rth
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read
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g
o
n
P
2X
recep
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rs
C
oddou
C
et
al.
(2011)
A
ctivation
an
d
regulation
of
purin
ergic
P2X
receptor
ch
an
n
els.
Pharm
acol
Rev
63
:641-83
[PM
ID
:21737531]
H
aberm
ach
er
C
etal.(2016)M
olecular
structure
an
d
fun
ction
ofP2X
receptors.
N
europharm
acology
104
:18-30
[PM
ID
:26231831]
Jacobson
,K
A
etal.(2016)M
edicin
alch
em
istry
ofaden
osin
e,P2Y
an
d
P2X
receptors.
N
europharm
a-
cology
104
:31-49
[PM
ID
:26686393]
K
h
akh
BS
et
al.
(2001)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
X
X
IV.
C
urren
t
status
of
th
e
n
om
en
clature
an
d
properties
of
P2X
receptors
an
d
th
eir
subun
its
Pharm
acol
Rev
53
:
107-118
[PM
ID
:11171941]
N
orth
,R
A
.(2016)
P2X
receptors.
Philos
Trans
R
Soc
Lond
B
BiolSci371
:[PM
ID
:27377721]
ZAC
Ligan
d-gated
ion
ch
an
n
els→
ZA
C
O
verview
:Th
e
zin
c-activated
ch
an
n
el(ZA
C
,n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
fo
r
th
e
Z
in
c
A
c-
tivated
C
h
an
n
el)
is
a
m
em
ber
of
th
e
C
ys-loop
fam
ily
th
at
in
-
cludes
th
e
n
icotin
ic
A
C
h
,5-H
T
3 ,G
A
BA
A
an
d
strych
n
in
e-sen
sitive
glycin
e
receptors
[78,
155,
363].
Th
e
ch
an
n
el
is
likely
to
exist
as
a
h
om
open
tam
er
of
4TM
subun
its
th
at
form
an
in
trin
sic
cation
selective
ch
an
n
el
equiperm
eable
to
N
a +,
K
+
an
d
C
s +,
but
im
per-
m
eable
to
C
a 2+
an
d
M
g
2+
[363].ZA
C
displays
con
stitutive
activity
th
at
can
be
blocked
by
tubocurarin
e
an
d
h
igh
con
cen
tration
s
of
C
a 2+
[363].A
lth
ough
den
oted
ZA
C
,th
e
ch
an
n
elis
m
ore
poten
tly
activated
by
proton
s
an
d
copper,
w
ith
greater
an
d
lesser
efficacy
th
an
zin
c,respectively
[363].ZA
C
is
presen
t
in
th
e
h
um
an
,ch
im
-
pan
zee,
dog,
cow
an
d
opossum
gen
om
es,
but
is
fun
ction
ally
ab-
sen
t
from
m
ouse,or
rat,gen
om
es
[78,155].
N
om
enclature
ZAC
H
G
N
C
,U
niProt
ZACN
,Q
401N
2
Endogenous
agonists
H
+
[363],C
u
2+
[363],Zn
2+
[78,363]
Antagonists
tubocurarine
(pIC
50
5.2)
[78],C
a 2+
(pIC
50
2)
[363]
FunctionalC
haracteristics
O
utw
ardly
rectifying
current
(both
constitutive
and
evoked
by
Zn
2+)
C
o
m
m
en
ts:
Th
e
ZA
C
subun
it
does
n
ot
appear
to
exist
in
th
e
m
ouse
or
rat
gen
om
es
[78].
A
lth
ough
tabulated
as
an
an
tagon
ist,
it
is
possible
th
at
tubocurarin
e
acts
as
a
ch
an
n
el
blocker.
A
n
tagon
ism
by
C
a 2+
is
voltage-in
depen
den
t.
ZA
C
is
n
ot
activated
(at
1
m
M
)
by
tran
sition
m
etals
in
cludin
g
Fe 2+,C
o
2+,N
i 2+,C
d
2+,or
A
l 3+
[363].
Th
e
con
cen
tration
respon
se
relation
sh
ip
to
C
u
2+
is
biph
asic,w
ith
con
cen
tration
s
exceedin
g
30
µ
M
bein
g
associated
w
ith
reduced
activation
[363].
Fu
rth
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read
in
g
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n
Z
A
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C
ollin
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G
L
et
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A
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n
els.
N
europharm
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:2-5
[PM
ID
:18655795]
Peralta,FA
etal.(2016)Zin
c
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A
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Ion
C
h
an
n
elM
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R
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M
etallo-
protein
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IntJM
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Trattn
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C
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[PM
ID
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